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Abstract 
As results of increasing life expectancy, the percentage of older population is growing fast. The increasing 
number of elderly and the increasing drug use among the elderly especially who have chronic disease, 
emphasizes the need to continuously monitor drug utilization in this group. This study aimed to explore 
the issue of adverse drug reactions among older people presenting at UNRWA-primary health care 
centers, also this thesis aimed at identifying individuals at risk of adverse drug reactions. 
A mixed- methods approach was used, in which data has been triangulated. The study included three 
groups; the first is 694 prescription drugs of older people had a mix of health problems and included at 
least 5 drugs which randomly selected from ten UNRWA-PHCs computer databases in the Gaza 
governorates. The second group was in-depth interviews with three Non-Communicable Disease 
physicians that selected randomly from three centers and the third group consists of three focus group 
discussions that conducted with purposely selected 23 participants. The Statistical Package for the Social 
Sciences Program has been used for data analysis including cross tabulation, percentages and mean for 
the quantitative data collection entry and analysis in addition to independent sample t-test while open 
coding thematic technique was used for the qualitative data.  
Findings revealed that 61.8% of participants were females, the mean age for females was (69.18) years 
(SD: 7.18), and for males was (68.36) years (SD: 7.21).  About 61.3% of participants were between 60 – 
69 years.  With regard to participant’s chronic morbidity, complicated hypertension with diabetes 
mellitus type 2 was the highest prevalence among elderly (52.6%), followed by hypertension (35.2%) and 
diabetes mellitus type 2 disease (5.8%). complicated hypertension with diabetes mellitus type 2 is higher 
among female than male patients (56.9% versus 45.2%) 
Concerning number of drugs prescribed in prescriptions, the minimum number was 5 drugs with a mean 
number of drugs per prescription was 6.78 drug and SD= 1.88. About 29.3% of prescriptions contain 5, 
24.6% had 6 drugs, and 19% had 7 drugs, and 27.1% had 8 drugs more. With regards to most drugs 
prescribed in elderly prescription, Aspirin was the most commonly drug prescribed as it was found in 
87.5% of prescriptions, followed by Enalapril which represent 63.7% of prescriptions, and Paracetamol 
found in 59.4% of prescriptions, while the lowest included digoxin found in 6.3% of prescriptions. 
By using drug checker to examine the possibility of adverse drug reactions between drugs, 93.9% of 
prescriptions included in the study show different types of adverse drug reactions; a significant adverse 
drug reactions were shown in 77.8% of prescriptions, in addition to serious ADR appears in 69.2% of 
prescriptions, and minor adverse drug reaction shown in 72%. Meaning that adverse drug reactions 
found in 93.9% of prescriptions that prescribed in UNRWA clinics. Interaction in 8 prescriptions included 
8 drugs and more was serious in 87.2% of prescriptions, and was significant in 94.1% of prescriptions.   
The study concluded that majority of health providers working in UNRWA clinics are not knowledgeable 
about ADRs. The prescription behavior requires further improvement. There is a need for training and 
monitoring programs accompanied by supervision and learning.  
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Chapter (1) Introduction 
1.1 Background 
As results of increasing life expectancy and decreasing mortality rates, globally, the older 
population is growing fast.  Currently, every ninth person in the world is aged 60 years and 
above. A definition of older person varies between countries; in developed countries the 
chronological age of 60 or 65 years, which is equivalent to retirement age, is the beginning 
of elderly period. While, in developing countries other aspects take place, such as changes 
in capabilities and in social role (Gorman, 2000).  
By 2050, the number of elderly people will increase sharply to one in five (WHO, 2011).  
This increasing in number of elderly population has tremendous social, cultural, and 
economical implications. With regard to healthcare services, older people utilize far more 
healthcare services that younger people.  
Generally, elderly people are more susceptible to medical disorders, in particular chronic 
diseases such as Hypertension (HTN), arthritis, heart diseases, and Diabetes Mellitus (DM). 
Thus, more health care providers and resources are required to meet the high demand for 
health services. Medication is one of the main health resources required to meet its demand. 
Administration of multiple medications or administration of more than indicated medications 
is called "polypharmacy." In addition to the financial burden of polypharmacy, it is one of 
main risk factors of Adverse Drug Reactions (ADR) among elderly people (Sharif et al., 
2008).   
Polypharmacy is determined either as the simultaneous use of a certain number of 
medications (5 or more) (Fialova et al., 2005) or as the unnecessary overuse of drugs (Avorn, 
2004). It can refer to perceptions of prescribers or consumers and may or may not include 
Over the-Counter (OTC) remedies. 
Elderly people are more likely to be admitted to hospitals because of ADR than any other 
age groups; this due to overuse of prescription of medication. Between 4% (Veehof et al., 
2000) and 34 % (Barat et al., 2000) of people aged 65 years and above are affected by 
polypharmacy. A number of studies investigated determinants of prescribed polypharmacy 
and reported relevant socio-demographic factors (age, gender, education, employment and 
socioeconomic status), (Odubanjo et al., 2004) influence of disease (multi-morbidity, 
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multiple complaints, well-being and chronic illness) (Al-Windi, 2005) and health system 
factors (prescriber related, perceived patient pressure and free access to medications) (Little 
et al., 2004). The effect of polypharmacy not only of the patent himself but also affect on the 
health system, according to Tangiisuran and colleagues (2009), for every dollar spent on 
medications in geriatric care nursing facilities, 1.33 dollars are required for the treatment of 
drug’s related morbidities and mortalities. Fortunately, about one-half of ADR among 
elderly people could be prevented by improving the prescribing process (Tangiisuran et al., 
2009). So the rational use of medicines is a crucial part of the national health policy and 
access to medicines is one of the vital tools needed to improve and maintain health.  
Escalating pharmaceutical costs, new budgetary demands and a growing awareness of health 
risks for patients with polypharmacy exert pressure on General Practitioners (GPs) to reduce 
prescription of medication. This necessitates a good understanding of how multiple drug use 
comes about. 
In the Gaza Strip (GS), the situation of elderly people, morbidity and mortality, is different 
when compared with global countries, this due to that GS lived under siege, closure, and 
poor health infrastructure. The prevalence of chronic diseases among older people appears 
to be high, as 68.6% of older people (60 years and above) in the GS have chronic diseases 
(PCBS, 2015).  In addition, United Nations Relief and Works Agency For Palestine Refugees 
in The Near East (UNRWA) reported that clients aged 40 years old and above represented 
91% of all clients who utilized services of the Non Communicable Disease (NCD) clinics 
within the Primary Health Care (PHC) centers (UNRWA, 2016).  
Regardless this figure and increasing chronic diseases in elder people, most research studies 
focused on women in reproductive age and children as they mostly considered as the 
vulnerable groups.  And some of international studies focus on drug use by the elderly in 
different countries. However, most of these studies focused on the prevalence and 
determinants of polypharmacy, while this thesis aimed to focus on the drug interactions due 
to polypharmacy in addition to the prevalence of polypharmacy. 
1.2. Research problem 
The use of polypharmacy is associated with well-known ADR. The efficacy of drugs may 
be reduced as results of different factors such as prescribing, dispensing and administration 
errors, in addition to patient non-adherence, and medication ineffectiveness. Prescribing 
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errors include irrational, inappropriate drug use and ineffective prescribing, under-
prescribing, and overprescribing (Hovstadius, 2010). As will be discussed later, ADR 
includes six categories: dose-related, non-dose-related, dose-related and time-related, time-
related, withdrawal, and failure of therapy (Edwards and Aronson, 2000).  
With regard to elderly people, globally, many research studies have shown a correlation 
between ADR and age (WHO, 2007). From the researcher work experience at private 
pharmacies, the researcher noticed and documented several cases of prescription errors that 
contributed to ADR, in particular among elderly clients. Within the context of GS, according 
to the researcher knowledge, no studies have examined the issue of ADR among elderly 
people in the GS, in particular among elderly people who are taking multi-drugs, 
polypharmacy. Thus, this study will be the first one to explore the issue of polypharmacy 
and ADR among elderly people in the GS.  
1.3. Justification of the study  
The prevalence of chronic diseases among older people in the GS appears to be high, as 
68.6% of older people (60 years and above) have chronic diseases, and women are more 
susceptible to develop chronic diseases than men (75.1% of females vs. 64.7% of males) 
(PCBS, 2015).    
According to UNRWA 2016 annual report, clients aged 40 years old and above represented 
91% of all clients who utilized services of Non Communicable Disease (NCD) clinics within 
the Primary Health Care (PHC) centers (UNRWA, 2016). Out of the total clients, 65 % of 
patients were female, reflecting the high utilization of health services by females and high 
accessibility of the UNRWA health services (UNRWA, 2016). The main health problems 
are HTN with a 44.5% and DM with 17.3% of the total registered patients and combination 
of HTN and DM with a 38.2% of total registered patients (UNRWA, 2016). According to 
the Palestinian Family Survey, which was conducted in 2010, elderly people rated their 
health conditions as: average with 44% of them, less than good with a 17 % of them, and 
bad with a 21 % of the total. Consistent with previous results, more women reported having 
less than good or poor health compared with men (PCBS, 2015). 
GS is a young society, as 44.3% of its population is aged less than 15 years old (PCBS, 
2015). On the other hand, only 3.7% of its population is aged 60 and more (PCBS, 2015). In 
the past two decades, the improvement in the socio-economic conditions and high 
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accessibility and affordability of health services contributed to decreasing in crude death rate 
and increasing the life expectancy to reach 72.1 years in the GS (70.7 for males and 73.5 for 
female) (PCBS, 2015). Consistent with the global trend, the percent of older women (60 
years and above) is higher than older men (60 years and above), with sex ratio reaches about 
80.5 males against 100 females (PCBS, 2015). The percent of older people who headed 
household reached to 13.1% in the GS (Romana et al., 2012). 
In Palestine, most research studies focused on women in reproductive age and children as 
they mostly considered as the vulnerable groups.  There are limited, if any, studies that were 
conducted to examine issues that are related to aging and elderly people. This study will be 
among the first studies that focus on elderly population. Furthermore, as research studies 
have shown that the polypharmacy is the main leading cause of ADR among elderly, this 
study will be the first to examine the impact of polypharmacy on ADR among the older 
people in the Gaza Strip; especially they are the main group who consumes drugs.  
1.4. Objective of the study 
1.4.1. General objective 
To explore the issue of ADRs among older people presenting at United Nations Relief and 
Works Agency for Palestine Refugees in the Near East (UNRWA) PHC centers in the Gaza 
Strip. 
1.4.2. Specific objectives of the study 
1- To determine the prevalence of ADR among older people presenting at UNRWA-PHC 
centers.  
2- To identify the most frequently used drugs among older people prescriptions at UNRWA-
PHC centers. 
3- To assess polypharmacy which leading to ADR among older people prescriptions at 
UNRWA- PHC centers.  
4- To assess awareness of health providers about ADR and prescription practices.  
5- To propose recommendations, in order to improve drug’s prescription for the older people 
in the Gaza Strip.  
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1.5. Research Questions 
1- What is the prevalence of ADRs among older people presenting at UNRWA- PHC 
centers? 
2- What are the most commonly used drugs among older people prescriptions at UNRWA-
PHC centers? 
3- Does polypharmacy lead to ADRs among older people presenting at UNRWA-PHC 
centers? 
4- Did the health provider aware about ADR and prescription practices 
5- What are the main provider’s risk factors for ADR? 
1.6 Context of the study  
1.6.1 Demographic context 
Occupied Palestine is a small country, its area about 26,323 sq. km (Annex 1). Now Palestine 
comprises two areas separated geographically, the West Bank (WB) and GS, with total area 
of 6,020 sq. km (Palestinian Centre Bureau of Statistics (PCBS, 2015). GS is a narrow band 
of land located on the south of Palestine, constituting the coastal zone of the Palestinian 
territory along the Mediterranean Sea between Egypt and the green line.  It is 45 Kilometres 
long and 6-12 Kilometres wide with an area of 365 sq. km (PASSIA, 2015).  
1.6.2 Economical context 
GS is very poor area with limited natural resources. Unemployment and poverty rates have 
increased dramatically in recent years due to the Israeli strict siege. The Gaza economy has 
been greatly affected during the last ten years due to a combination of unemployment, 
closures, and restrictions placed on workers and industries. Unemployment in Gaza reached 
very high levels. It was reported that unemployment rates in GS reached 65 %, and that 
poverty rates reached up to 80%, due to the ongoing Israeli-led siege and repeated attacks 
against GS. Furthermore, 80% of the residents in the strip depend on humanitarian aid 
provided by different relief groups such as UNRWA and World Food Program. The ongoing 
siege forced 96% of the factories and industrial areas in GS to shut down as the closure of 
border terminals blocked exports and also blocked imports of tools and equipment needed 
by the factories to continue the production process (Bannoura, 2009). 
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1.6.3 Health care system  
Health care services in Palestine are provided by five sectors, which is Ministry of Health 
(MOH), UNRWA, Medical Military Services, Non-Governmental Organizations (NGOs) 
and private sector.  MOH is the main health care provider; it provides primary, secondary 
and tertiary services and purchases some services from private providers locally and abroad. 
MOH plays the main role in providing and controlling immunizations scheme, public health 
activities, licensing and registration of health facilities (MOH, 2015). Health care financing 
is mainly provided through the government, apart from the out-of-pocket health financing 
which is the first source of health financing in Palestine (MOH, 2015). 
Additionally, external donations constitute a considerable source for health funding. 
UNRWA mainly provides primary health care services to the refugee population. UNRWA 
operates 22 PHC centres in GS (Annex 2). The NGOs sector is extensive: from missionary 
hospitals (As Ahli Arab Hospital, Al-Awda Hospital), to facilities supported by international 
organizations, to community health centers. The NGOs sector operates 57 centers (WHO, 
2009).  
1.6.4 Primary Health Care Services in the Gaza Strip 
PHC is one of the most important components of the Palestinian health care system. PHC 
centers provide accessible and affordable health services for all Palestinians, especially for 
children and other vulnerable groups (MOH, 2015). The MOH is working with other health 
sectors in providing the primary health services, mainly UNRWA, NGOs and Palestinian 
Military Medical Services PMMS (MOH, 2015).  Total number of registered PHC centers 
in Palestine is 748 centers, of them, 147 centers in the GS.  
The MOH owns and operates 54 PHC centers; these centers are classified according to the 
provided health care services. From the 54 PHC centers, there are 29 centers offer secondary 
health care services, 16 centers offer rehabilitation services. These centers offer different 
health services according to the level of the clinic including MCH care, family planning, 
dental, mental services and others (MOH, 2015). Out of the 54 PHC centers, only 9 centers 
were classified as fourth level. 
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In the GS, UNRWA provides health-care services to over 1.2 million refugees through 22 
PHC centers distributed across the Gaza Strip. The UNRWA`s services includes but not 
limited to daily care, care of chronic diseases, family planning, and infectious diseases 
(UNRWA, 2016). 
1.6.5 Drugs situation in Gaza Strip  
The Palestinian National Authority (PNA) gave more courtesy for drugs sectors in GS and 
WB, the thing that leads to satisfied quality and availability of drugs in governmental sector 
at normal state, but the political restriction was the major reason to disruption of drugs supply 
(Obeidallah et al., 2000). The drugs cost at the private sector is quite expensive due to lack 
of international competition for Palestinians pharmaceutical market because Israel applies 
restriction to protect its own market (Obeidallah et al., 2000)., in addition to that the declined 
economic condition has increase the drugs demands in governmental sector.  
In comparison with neighboring countries at the same level of economic condition, 
consumption of drugs in the WB and the GS is very high (Obeidallah et al., 2000). Absence 
of appropriate drugs policy, and inadequate source for drugs information, led strong patient 
demand and over prescription (Obeidallah et al., 2000). Over use of antibiotics in 
governmental PHC in the GS, where it represent33% from total PHC drugs expenditure in 
2005 (MOH, 2006), in 1997 48% of patients were prescribed antibiotics (Obeidallah et al., 
2000), which is a clear indicator of irrational use of drugs in GS. Over use of antibiotics lead 
to resistance of bacteria and ineffective therapy, and finally lead to ineffective cost uses of 
drugs. Random use of drugs is a type of wastage, which is worrying problem for PNA, 
because of scarcity of its resource. 
1.6.6 Development of Essential Drugs Lists (EDL) 
 In 1975 when the first effort from WHO regarding the development of essential drugs policy 
was done as a result of recommendation from World Health Assembly in resolution  which 
request WHO to develop means to assist different countries in developing their 
pharmaceutical programs such as selection, procurement of drugs based on country health 
need (WHO, 1998). In 1977 WHO published the first WHO model list of essential drugs, 
which then adopted as one of the eight elements of primary health care during 
WHO/UNICEF Conference on Primary Health Care at Alma-Ata, 1978. Followed by many 
activities to improve the pharmaceutical situation in countries, such as Conference of Experts 
8 
 
on Rational Use of Drugs in Nairobi in 1985 and in 1986 published Guidelines for 
developing national drug policies. The activities are continuous and developed over years 
(WHO, 1998). At present, most of WHO Member States had a national essential drug list, 
in over 90 countries the essential drugs concept introduced into the pharmacy collage 
curriculum (WHO, 2002). In Palestine the first step to establish essential drugs list was in 
1997 when two list of 550 drugs in Gaza Strip and 700 Drugs in West Bank independently 
choosing, then two lists are merged into one list and compared by WHO EDL, and then the 
draft list reviewed by World Bank consultant (WHO, 2001). Finally, Palestinian EDL was 
approved by MOH on March 2000, followed by training courses on EDL and Palestinian 
National Formulary (PNF) using (MOH, 2001). All health ministries including Palestinian 
MOH determines specific drugs to be available in its PHC centers according to community 
priorities. Suitable drugs list will lead reduce the overuse of drugs and to control 
expenditures. If the drugs list in Governmental PHC is not suitable, it may success to reduce 
drugs use and health care utilization, but it also may increase patient drugs expenditure from 
private sector. 
1.6.7 Drugs use indicators.  
As one action on essential program, WHO develop simple indicator as tool to investigate 
drugs use in health facilities, include core drugs use indicator and complementary indicators. 
Core drugs use indicators are highly standardized, and don’t need national adaptation. It 
consists from three major categories; pharmaceutical prescribing practices of health 
providers, key elements of patient care covering both clinical consultation and 
pharmaceutical dispensing and availability of facility-specific factors that promote rational 
drugs use. Drugs use indicators considered as quick and reliable tools to assist different 
aspects of drugs used in PHC, and recommended for inclusion in all studies related to drugs 
use, then the results are more examination in more detail. Complementary indicators are less 
standardized, and difficult to measure (WHO, 1993).  
A research result of a study done in Nigeria in 1999 with the support of Action Program of 
essential Drugs DAP-WHO itemed by; "The development of standard values for the WHO 
drug use prescribing indicators" was introduced during International Conferences on 
Improving Use of Medicines. The results were as in following; Average number of drugs per 
prescription (1.6-1.8), Percentage of prescriptions with an antibiotic prescribed (20%-
26.8%). However, standards for the indicators may not be globally generalized since the 
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clinical case mix, which is the main determinant of the indices, may be influenced to varying 
degrees by other local factors (Isah et al., 1999). After that, many studies conducted 
regarding use indicators and in light of their results the WHO submitted drug recommended 
standards values for drug use indicators as following; Average number of drugs per 
prescription (2), percentage of prescriptions with an antibiotic prescribed (less than 30%) 
(WHO, 2006). And recommend being the availability of essential key drug 100% during 
different time of month WHO, 2006). 
1.7 Definition of terms 
Adverse drug reactions 
It is commonly defined as: “A response to a drug that is noxious and unintended and occurs 
at doses normally used in man for the prophylaxis, diagnosis or therapy of disease or for 
modification of physiological functions.” (WHO, 1979). 
Elderly-Aging:  
The modest description of age is the chronological count of calendar years (Jyrkämä, 1995). 
Many elderly persons do not feel themselves old even when retired or at the advanced age 
of 75 old (Devroey, Casteren and Walckiers, 2002).   
Polypharmacy: 
It is defined simply as the use of multiple medications by a patient. The precise minimum 
number of medications used to define "Polypharmacy" is variable, but generally ranges from 
5 to 10 (Nomura, 2011). 
 
1.8 Lay out of the study 
This study consists mainly from five chapters: introduction, conceptual framework and 
literature review, methodology, results and discussion, conclusion and recommendations. 
The first chapter presented general introduction to the study, where a brief background 
regarding the subject of the study was provided. The researcher illustrated the problem 
statement, justification for conducting the study, the general goal and specific objectives, 
research questions, definition of terms and context of the study. 
The second chapter included two parts; conceptual framework where the researcher provided 
a schematic diagram of the conceptual framework of the study, and the second part presented 
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the literature review related to the study topic and variables. In-depth detailed theoretical 
inquiry including previous studies was presented to enrich the study. 
The third chapter described methodology including study design, population, sample, 
instruments, pilot study including validity and reliability of study instruments, ethical 
considerations, and statistical analysis procedures. 
The fourth chapter presented the study results and discussion. The researcher presented the 
results in form of figures and tables that make it easy for the reader to understand and make 
comments. The results were discussed in relation to available previous studies that directly 
related to the topic of this study and its objectives. 
Finally, in the fifth chapter, the researcher presented conclusion, recommendations, and 
suggestions for further research in the light of the study results.    
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Chapter (2) Literature review 
To achieve the research goals and objectives presented in chapter one, the researcher 
developed a conceptual framework based on literature review that describes all the study 
domains. Furthermore, it provides a comprehensive review of different studies that were 
conducted in the region and other countries. 
2.1. Conceptual framework 
There are different factors that lead to ADR. As shown in figure 2.1, there are factors related 
to health provider’s prescription practices. Very short consultation time that does not allow 
sufficient time to make a proper diagnosis and very short patient-dispenser interaction time 
that does not allow sufficient time to explain to patients how to take their medicines and 
insufficient health education.  
2.1.1 Polypharmacy related factors and knowledge:  
Polypharmacy is defined simply as the use of multiple medications by a patient. The precise 
minimum number of medications used to define "Polypharmacy" is variable, but generally 
ranges from 5 to 10 (Ferner and Aronson, 2006). Polypharmacy will be examined through 
reviewing client’s medical record. The reviewed medical records that have at least five drugs 
will be considered as “polypharmacy”. The researcher will also assess the drug groups and 
rationality of the prescribed drugs. Regarding to the knowledge about side effect of the 
medication, the researcher will assess this factor through conducting focus group discussions 
with health providers. 
2.1.2 Health Providers related Factors 
Health care professionals are accountable to confirm safe dispensing and use of drug 
regimens involving the use of drug combinations that may interact and cause serious adverse 
events. Furthermore, the consultation time was checked by the assessing the mean number 
of clients followed by each health providers per day. Additionally, the researcher examines 
physicians’ prescribing practices and knowledge on ADR and polypharmacy.  
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2.1.3 Health System related factors:  
Regarding to healthcare system factors, the researcher assesses the adherence of health 
providers with protocols and policies, if any. The researcher also assess the supervision and 
monitoring within the primary health care centers 
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Figure (2.1) Conceptual framework 
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2.2 Literature review 
2.2.1 Aging definition 
The modest description of age is the chronological count of calendar years (Jyrkämä, 1995). 
Many elderly persons do not feel themselves old even when retired or at the advanced age 
of 75 old (Devroey, Casteren and Walckiers, 2002). 
Aging is also defined most simply as a biological, psychological, and social phenomenon. 
Biological aging is related with changes in the human organism and biological aging 
processes. Biological age is an attribute of body tissue relevant to pathogenesis (Last, 1995). 
Pharmacokinetic and pharmacodynamics changes of drug efficacy are connected with the 
biological aging of the elderly (Pollock, 1998). The main organs affected by aging are the 
kidneys, the liver, and the cardiovascular and central nervous systems (Pollock, 1998).  
Aging may cause changes in the neurotransmission systems and these changes may increase 
sensitivity to sedation by drugs (Veehof, 2000). Psychological aging occur in the 
individual’s psychic activities. Social aging is linked with the person as a member of society, 
and the term “the elderly” generally refers to people who have reached the socio-political 
age of 65 years. Social aging is more complicated to define than either biological or 
psychological aging, and the definitions partly overlap. Social aging is associated with 
changes that take place in the individual’s or social group’s relationship with their 
environment and these changes may manifest at both individual and societal levels (Pollock, 
1998). 
2.2.1.1 Aging and health  
The international demographic transition is characterized by decreasing fertility and 
mortality rates with continuously growing elderly populations. The developed countries 
have experienced this for years, as well as it is now also evident for the developing countries, 
where both the absolute and relative numbers of elderly persons are increasing fast, with 80 
years and older is the fastest growing age group. In 1950, people 80 years and older 
constituted 1% of the population in the developed countries and 0.3% in the developing 
countries. In 2000 the corresponding figures were 3.1% and 0.7%, and the projections for 
2050 are 9.4% and 3.6%, respectively. In absolute numbers, the world population 80 years 
and older is expected to increase from 70 million people in 2000 to almost 400 million people 
in 2050, with seven out of ten living in the developing countries (United Nations, 2006). 
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In the occupied Palestinian territory, the number and percentage of elderly residents aged 
60+ is possible to increase. With increasing age, multi-morbidity becomes more frequent, 
leading to higher occurrence of medication use and higher risk of adverse drug reactions due 
to polypharmacy, chronic diseases, and age-related changes in pharmacokinetics 
(absorption, distribution, metabolism and elimination of a drug in the body) and 
pharmacodynamics (the pharmacologic effect and clinical response to the drug) (Mangoni 
& Jackson. 2003). Conditions of Palestinian elderly are not very much different from those 
around the world; elderly in Palestine represent 3% of population in Palestinian territory 
(Population Reference Bureau, 2007); Life expectancy at birth in the Palestinian territory is 
71 years for males, and 74 years for females (Population Reference Bureau, 2007).  
2.2.2 Polypharmacy definition 
Polypharmacy is defined simply as the use of multiple medications by a patient. The precise 
minimum number of medications used to define "Polypharmacy" is variable, but generally 
ranges from 5 to 10 (Ferner and Aronson, 2006). While polypharmacy most commonly refers 
to prescribed medications, it is significant to moreover consider the number of over-the-
counter and herbal/supplements used. 
The issue of polypharmacy is of exact concern in older people who, compared with younger 
individuals, tend to have more disease conditions for which therapies are prescribed. It has 
been estimated that 20 percent of Medicare beneficiaries have five or more chronic 
conditions and 50 percent receive five or more medications (Tinetti et al., 2004).  Among 
ambulatory older adults with cancer, 84 percent were receiving five or more and 43 percent 
were receiving 10 or more medications, in one study (Nightingale et al., 2015). 
The use of larger numbers of drug therapies has been independently associated with an 
increased risk for an ADE, irrespective of age (Field et al., 2001), and increased risk of 
hospital admission (Lu et al., 2015). Though, it is difficult to eliminate the impact of 
confounding factors in considering the relationship between polypharmacy and a variety of 
outcomes in observational studies (Fried et al., 2014). 
A balance is required between over- and under-prescribing.  Multiple medications are often 
required to manage clinically complex older adults. Clinicians are often challenged with the 
need to match the complex needs of their older patients with those of disease-specific clinical 
practice guidelines. For a hypothetical older female patient with chronic obstructive 
pulmonary disease, type 2 diabetes, osteoporosis, hypertension, and osteoarthritis, clinical 
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practice guidelines would recommend prescribing 12 medications for this individual (Boyd 
et al., 2005). 
A number of studies, using older versions of the Beers criteria, have recognized that use of 
drugs known as "inappropriate" was prevalent in the US, Canada, and Europe (Fialová et al., 
2005). In a sample of community-dwelling older adults in the United States, 43% used at 
least one medication that would be deemed potentially inappropriate by the updated Beers 
criteria, with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) being the most common 
(Davidoff et al., 2015).  Additional study, using Medicare data and the 2012 Beers criteria, 
showed that the point prevalence in each calendar month of potentially inappropriate 
medications used in adults ≥65 years was 34.2% in 2012 (Jirón et al., 2016). 
Some of the inappropriate drug therapies known on the Beers list are available as over-the-
counter products (Rochon et al., 2004). This reinforces the need to always consider over-
the-counter drug therapies when reviewing a patient's medications and to educate individuals 
on potential problems that can arise from the use of OTC preparations. 
2.2.3 Adverse drug reaction definition  
An ADR is commonly defined as: “An injury resulting from medical intervention relating to 
the drug” (Bates et al., 1997).  Another commonly accepted definition of ADE is that offered 
by the International Conference on Harmonization Guidelines (FDA), designed to be broad 
and inclusive, it states: “Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment.” 
Classically, ADR is defined as a Type A or Type B reaction (Rawlins and Thompson, 1977), 
where a Type A reaction is common, dose dependent, due to an extension of the known 
pharmacological effects of the drug and hence predictable. In difference a Type B reaction 
is not dose dependent or related to the known pharmacological profile of the drug, being 
seen as a bizarre unpredictable reaction. 
Granting there are several other definitions of an ADR existing, the most widely used was 
initially developed by the WHO in 1979 and modified by Edward & Aronson in 2000 which 
defined as: “A response to a drug that is noxious and unintended and occurs at doses 
normally used in man for the prophylaxis, diagnosis or therapy of disease or for modification 
of physiological functions.”  
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2.2.4 Category of adverse drug reactions 
Adverse drug reactions have been categorized, by Nebeker and colleagues (2004), into five 
different groups: 
i. Adverse drug reactions,  
ii. Medication errors,  
iii. Therapeutic failures, 
iv. Adverse drug withdrawal events, and 
v. Overdoses (Nebeker et al., 2004). 
The researcher used in this research to investigate the Adverse Drug Reaction within 
prescriptions included polypharmacy  
2.2.5 Rational of taking many medications by elderly 
Numerous factors contribute to polypharmacy among patients over age 65. Clinicians may 
be prescribing extra drugs for their elderly patients than they have in the past, simply because 
there are more drugs offered for treating these patients. The detection of a broad range of 
pharmaceuticals for a wide variety of conditions has assisted many patients. Inappropriately, 
this new development has also led to both overuse and inappropriate use of prescription 
medications (Wooten and Galavis, 2005). 
Several drugs that were once available only with a prescription, such as omeprazole and 
loratidine are nowadays readily available over the counter, and their use is on the rise in the 
United States. Furthermore, complementary and alternative medicines, such as herbal 
therapies, are becoming increasingly popular among all patients, including the elderly 
(Fulton and Allen, 2005). 
Compared to the general inhabitants, a patient over 65 is more likely to have several chronic 
disorders, each requiring at least one medication (Zahn et al., 2001). Elderly patients with 
more than one health illness are likely to receive care from several healthcare providers, each 
of whom may prescribe a different medication to treat the same symptoms (Conry, 2000). 
Additional factor in the equation is what's called the prescribing cascade: An elderly patient 
progresses side effects from a medication he's taking; though, his healthcare provider 
interprets the symptoms not as side effects of the drug but as symptoms of a disease. The 
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healthcare provider then prescribes yet another drug, creating the potential for even more 
side effects (Williams, 2002). 
2.2.6 Extent of the problem 
Adverse drug reactions (ADRs), including interactions, in older people are a common cause 
of admission to hospital (Mannesse et al., 1997), are common in elderly patients in hospital 
(Mannesse et al., 2000), and are an important cause of morbidity and death.   
Even after excluding errors in drug administration, noncompliance, overdose, drug abuse, 
therapeutic failures, and possible ADRs, Lazarou and collages found the overall incidence 
of serious ADRs in the general hospitalized population of the USA to be 6.7% (Lazarou, 
Pomeranz, and Corey, 2000). The incidence of fatal ADRs was 0.32% amongst patients from 
39 prospective studies included in this meta-analysis (Lazarou, Pomeranz, and Corey, 2000). 
Thus, ADRs are likely to be between the fourth and sixth leading cause of death in the USA. 
The evidence quickly dispels any complacency or suggestion that this problem is not an 
international one. An excellent systematic review by Wiffen et al. showed that the incidence 
of ADRs in European studies was around twice that in the USA, in those conducted either 
before or after an arbitrary cut-off date of 1985. The ADR rate for the USA and Europe 
studies was even greater (20%) than in studies carried out in general medicine settings 
(Wiffen et al., 2002). Few would argue that this rate of ADRs is not a major public health 
problem.  
There has been much debate on whether advancing age per se is a cause of increased risk of 
ADRs. Gurwitz and Avorn concluded that ‘patient-specific physiological and functional 
characteristics are probably more important than any chronological measure in predicting 
both adverse and beneficial outcomes associated with specific drug therapies’(Gurwitz and 
Avorn, 1991).  
ADRs were associated with polypharmacy, the mean number of drugs per patient in the ADR 
group being 7.8, compared with 3.3 amongst residents who did not experience them (Cooper, 
1996).  Other studies have also clearly shown that the risk of ADRs (including interactions) 
is related to the number of medicines taken (Carbonin et al., 1991), and that the elderly 
receive more medicines, sometimes inappropriately.  Thus, many studies from around the 
world show a correlation between increasing age and ADR rate, at least for some medical 
conditions (Dormann et al., 2001). 
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2.2.7 Burden of ADR on patient 
Further having an important effect on patient mortality, ADR moreover have a significant 
impact on morbidity of the client, with major financial implications on institutions and health 
care systems. With respect to mortality, in-hospital ADR is considered the  seventh most 
common cause of death in a recent Swedish study (Wester et al., 2008).   
More strikingly, Green and colleagues (2004) recognized that over 2% of clients admitted 
to hospital due to an ADR died, suggesting that these events may be responsible for the death 
of 0.15% of all clients admitted over a six month study period.  
ADR furthermore have an effect on client morbidity. On individual patient level, ADR may 
also decrease quality of life by causing worries and emotionally affect the clients belief in 
the use of medication for treatment. In confident cases, ADR were recognized as cause for 
GP visits and too, in severe cases, causing hospitalization.  ADR that occur during hospital 
stay were identified to extend the hospital stay (Davies et al., 2009). For example, the median 
length of stay for clients suffering ADR was 12 days significantly longer, as compared to 
patients in a non-ADR group, in a recently published study reporting the incidence of ADR 
during in-patients stay (Davies et al., 2009). 
 ADR also attributed to prescribing new medication to treat the adverse reaction that occurs 
in client that increases the drug use in those clients.  
Litigation is another burden of ADR that is frequently overlooked. A retrospective analysis 
of a New England malpractice insurance company claim record found that adverse drug 
events represented 6.3% of claims, of which 73% were judged preventable (Rothschild et 
al., 2002). Long term physician-client’s relationship could also be affected due to loss of 
trust. Litigation on the healthcare provider can besides be professionally and emotionally 
distressing (Studdert et al., 2000). 
2.2.8 Burden of ADR on organizations  
The increases in costs due to ADR are also due to the increased length of hospital stay and 
furthermore medical care provided to the patients.  Earlier reports on cost of ADR were 
based on US studies.  Classen et al., (1997) expected that hospitalization due to ADR 
increased the cost of patient care by $2,262 per-patient (Classen et al., 1997).   
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The Audit Commission calculated that ADR caused by medicines and medication error cost 
the National Health Service in England £0.5 billion yearly, due to longer hospital stays 
(Department of Health, 2001a).  This projection was based on the finding that the median 
bed stay in clients with ADR was eight days. This figure is comparable to estimates which 
were calculated based on the Department of Health statistics, where Wiffen et al., (2002) 
calculated ADR were likely to have caused over 1.5milion extra bed-days, with a cost to the 
NHS of £380 million in 1994 (Wiffen et al., 2002). 
2.2.9 Quality measures of drug prescribing 
Several factors contribute to the appropriateness and overall quality of drug prescribing. 
These factors comprise avoidance of inappropriate medications, appropriate use of indicated 
medications, monitoring for side effects and drug levels, avoidance of drug-drug 
interactions, and involvement of the client and integration of client values (Spinewine et al., 
2007). 
Measures of the quality of prescribing often focus on one or some of these factors, but rarely 
on all. Moreover, the predictive value of these measures of "quality of prescribing" in 
determining important long-term outcomes of care have not been determined. Approaches 
to decrease inappropriate prescribing in older adults include educational interventions, 
computerized order entry and decision support, multidisciplinary team care led by 
physicians, clinical pharmacists, and combinations of these approaches.  Available data for 
these interventions generally show significant improvements in inappropriate prescribing 
but mixed results for health outcomes or costs (Alldred  et al., 2016).  
A 2016 systematic review of eight studies of different prescribing interventions in long-term 
care homes (medication review, case conferences, staff education, clinical decision support 
technology, and/or some combination of these) reveled no effect of the interventions on 
hospital admissions, ADEs, and mortality (Alldred  et al., 2016). The studies that evaluated 
medication-related problems, appropriate prescribing, or cost of medication presented some 
evidence that interventions helped the recognition and solving of medication problems.  
A previous 2008 systematic review of 10 studies of computerized physician order entry with 
clinical decision support showed a mixed effect on reduction in ADEs, with five studies that 
showed a statistically significant reduction in ADEs, four that showed nonsignificant 
decrease, and one study that showed no impact on rate of ADEs (Wolfstadt et al., 2008). 
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2.2.10 Physicians and appropriate prescribing 
The physician who cares for aging patients with numerous chronic medical conditions must 
make daily decisions about appropriate drug therapy. More than 60% of all physician visits 
include a prescription for medication. The multiple medications and complex drug schedules 
may be justified for older persons with complex medical problems. However, the use of too 
many medications can pose problems of serious adverse drug events and drug-drug 
interactions, and often can contribute to non-adherence (Hepler and Strand, 1990) 
Health care professionals are responsible to confirm safe dispensing and use of drug 
involving the use of drug combinations that may interact and cause thoughtful adverse 
events. In the last 40 years an enormous amount of data on drug interactions has been 
published. Nonetheless, while potential drug interactions are probably common, only rare of 
them manifest thoughtful adverse events and often only in predisposed clients. Thus, health 
care professionals ‘sense inundated with hints for potential drug interactions of questionable 
clinical significance provided by their drug interactions information sources. Computerized 
alerts systems allow important assistance but their performance is not satisfying (Tamblyn 
et al., 2003). 
2.2.11 Physicians and reducing polypharmacy 
To prevent an iatrogenic disorder caused by over-prescribing, it is significant to reflect any 
new signs and symptoms in an older patient to be a possible significance of current drug 
therapy.  Coons and college (1994) identify 10-step approach to help reduce polypharmacy 
has been described as illustrated; 
1. Have patients "brown bag" all medications at each office visit, and keep an accurate record 
of all medications, including over-the counter medications and herbs. 
2. Get into the habit of identifying all drugs by generic name and drug class. 
3. Make certain the drug being prescribed has a clinical indication. 
4. Know the side-effect profile of the drugs being prescribed. 
5. Understand how pharmacokinetics and pharmacodynamics of aging increase the risk of 
adverse drug events. 
6. Stop any drug without known benefit. 
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7. Stop any drug without a clinical indication. 
8. Attempt to substitute a less toxic drug. 
9. Be-aware of the prescribing cascade (treating an adverse drug reaction as an illness with 
another drug). 
10. As much as possible, use the motto, "one disease, one drug, once-aday (Coons et al., 
1994).  
Another way to avoid adverse drug events is to use lower dosages for older patients. Many 
popular drugs do not have effective lower-dosage recommendations from the manufacturers. 
Physicians should remember to start low and go slow. Starting with one third to one half of 
the recommended dosage may help eliminate potential harmful effects (Coons et al., 1994).  
2.2.12 Risk of experiencing ADR 
2.2.11.1 Multifactorial issues 
 As the burden of ADR is seen to be higher in older clients, numerous factors have been 
drawn to logically clarify the condition. Though, these factors; poly-pharmacy, drug 
interactions, multiple chronic disease, reduced physiological capacity, reduced organ 
perfusion, and altered kinetics and dynamic have a complex, multidimensional relationship 
to each other. The increased risk of ADR is mainly due to; poly-pharmacy (including 
prescribed and non-prescribed medication) and physiological changes affecting the 
pharmacokinetics and pharmacodynamics of many drugs, or poor adherence due to cognitive 
impairment or depression (El Desoky, 2007). 
 Furthermore, the presentations of ADR are often atypical and non-specific or may be 
attributed to "frailty", or to the onset of a new medical problem. For example: falls, delirium, 
drowsiness, lethargy, light-headedness, apathy, urinary incontinence, chronic dyspepsia, are 
often accepted as a primary diagnoses rather than secondary to medications (Tangiisuran et 
al., 2009) 
2.2.11.2 Pharmacokinetic and pharmacodynamics changes 
 While many factors play a significant role in increasing the risk of ADR, with ageing the 
primary attributes are due to decrease in the physical reserves that effect the distribution, 
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metabolism, and excretion of drugs and also in changes in what the body does to the drug 
and in what the drug does to the body (Mannesse and van der Cammen, 2003).  
In addition, changes  in the body organs like renal, liver and lean body mass can contribute 
to the occurrence of ADR even without recent changes in the drug regimen (Mangoni and 
Jackson, 2003). Furthermore, presence of chronic diseases contributes by reduction in serum 
albumin and hepatic enzyme activity.  
Most pharmacokinetic changes are unavoidable and predictable based on physiological and 
organ changes due to ageing process. For example, a reduced hepatic drug clearance, lower 
first-pass effect and slower biotransformation for certain drugs can be explained by a decline 
in liver mass, blood flow, and a reduction of in vitro and in vivo metabolic capacity in the 
older person (Zeeh and Platt, 2002). 
2.2.11.3 Polypharmacy and multiple pathology 
 Polypharmacy, which is defined as concurrent use of several medicines (Nguyen et al., 
2006), is common in the elderly and frequently identified as an independent predictor of 
ADR. Two studies have revealed a positive correlation between the use of ≥9 scheduled 
medication and the risk of ADR (Field et al., 2001). These studies were conducted in nursing 
home residents.  
A recent study by Davies et al (2009) established numbers of medication as the only 
independent predictor of ADR, that occur during hospital stay with a hazard ratio of 1.14  
(Davies et al., 2009). Other studies also found alike relationship (Leendertse et al., 2008, 
Zopf et al., 2008). Polypharmacy also increases drug interactions, falls, hospital admission, 
length of hospital stay, hospital readmission, and mortality (Campbell et al., 2004).  
Publication of robust studies confirming the benefit of pharmacological treatment in primary 
and secondary prevention of chronic diseases in older clients moreover contributes to high 
use of medicines. Additionally, changes in prescribing habit which are supported by 
evidence-based medicine, further contribute to this condition. For example, more patients 
who are greater than 80 years old are being prescribed antihypertensive agents after the 
publication of HYVET study, which provides the evidence of the benefit of antihypertensive 
treatment in this patient age group (Beckett et al., 2008). 
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2.2.11.4 The prescribing cascade 
 The prescribing cascade is a term used to describe when a new drug is prescribed, to treat 
symptoms arising as a result of an unrecognized adverse event related to existing drug 
therapy (Rochon et al., 2004). This increases the risk of developing additional reactions 
related to new and potentially inappropriate treatment. Older people who are already on 
multiple medications are at increased risk of prescribing cascade, since discrimination and 
identification of drug related symptoms are the most challenging. 
2.2.11.5 Drug interactions 
 Drug–drug interaction may also increase the risk of an ADR with concurrent use of multiple 
medications, which are commonly used in older clients (Holbrook et al., 2005). An example 
would be concurrent use of warfarin, NSAIDs, Selective Serotonin Reuptake Inhibitors 
(SSRIs), omeprazole, lipid lowering agents, amiodarone, and fluorouracil, which may 
increase the risk of bleeding (Holbrook et al., 2005). The relationship between drug 
interaction and ADR were concisely mentioned in a recent study. Davies et al. (2009) 
reported 59% of the total ADR identified in their study were linked with drug interaction, of 
which, 91.7% were classified as pharmacodynamics interactions and 5.3% pharmacokinetic 
in origin and the remaining 3% due to mixed mechanism.  
2.2.11.6 Other contributing factors 
 Inappropriate prescribing is stated to be relatively common mainly in older clients 
(Hamilton et al., 2009). Hajjar and colleagues showed that 44% of frail elderly patients were 
prescribed at least one unnecessary drug (Hajjar et al., 2005).  On the other hand, Laroche et 
al. found inappropriate medication use as not the major cause of ADR in the elderly (Laroche 
et al., 2007) 
Older people are treated by physicains from different specialties due to multiple diseases. 
An expert consensus panel listed multiple prescribers as a potential risk factor for ADE in 
older patients (Hajjar et al., 2003). Green et al. also confirmed that the number of prescribing 
physicians as independent risk factors for patients self-reporting an ADE in an outpatients 
setting (Green et al., 2004).  
Even though the risk of having an adverse drug event has been shown to increase in older 
clients with greater cognitive impairment (Ganjavi et al., 2007), there are studies that 
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contradict this relationship, where cognitive impairment was associated with a reduced risk 
of ADR (Onder et al., 2002). Though, the intricacy of identifying ADR in older people due 
to the complexity of the client’s condition contributed to this result. For example, an older 
person with cognitive impairment is unable to communicate their problem to the treating 
physician. Lack of thorough assessment by physicians can cause them to overlook the 
medicine related symptoms and fail to identify ADR (Onder et al., 2002). 
2.2.11.7 Drug interaction checker  
Medscape is the leading online global destination for physicians and healthcare professionals 
worldwide, offering the latest medical news and expert perspectives; essential point-of-care 
drug and disease information; and relevant professional education. In May 1995, Medscape, 
Inc. was launched in New York's Silicon Alley by SCP  Communications, Inc., under the 
direction of Peter Frishauf. 
In February 1999, medical editor George D. Lundberg was hired as the editor-in-chief of 
Medscape. For 17 years prior to joining Medscape he had served as Editor of the Journal of 
the American Medical Association. In September of that year, Medscape, Inc. went public 
and began trading on NASDAQ under the symbol Melbourne School of Continental 
Philosophy (MSCP). In May 2000, Medscape merged with MedicaLogic, Inc., another 
public company. MedicaLogic filed for bankruptcy within 18 months and sold Medscape to 
WebMD in December 2001. In 2008, Lundberg was terminated by WebMD. The following 
year, it was announced that no new articles would be accepted for the Medscape Journal of 
Medicine, a Medscape journal that Lundberg started in 1999 (Romaine  Brown and  
Lundberg, 2009).  In 2009, WebMD released an iOS application of Medscape Continuing 
Medical Education (CME), (Dolan, 2009) followed by an Android version two years later 
(Einerson, 2011). 
Medscape provides many health services and tools; of them drug interaction checker. The 
drug interaction checker service does not endorse drugs, diagnose patients, or recommend 
therapy. The Service is an informational resource designed to assist licensed healthcare 
practitioners in caring for their patients and provide consumers with drug specific information. 
Healthcare practitioners should use their professional judgment in using the information 
provided. The Service is not a substitute for the care provided by licensed healthcare practitioners 
and consumers are urged to consult with their healthcare practitioner in all instances. The 
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absence of a warning for a given drug or combination thereof in no way should be construed to 
indicate that the drug or combination is safe, effective or appropriate for any given patient. 
The Drug Interaction Checker explains the mechanism of each drug interaction, and its classified 
the interaction into (strong, significant or minor), and in certain cases, can provide the 
recommended course of action to manage the interaction (Annex 3). The Drug Interaction 
Checker will also display any interactions between your chosen drugs and food. A significant 
ADR is defined as any unexpected, unintended, undesired, or excessive response to a drug that 
requires discontinuing the drug (therapeutic or diagnostic), requires changing the drug therapy, 
requires modifying the dose (except for minor dosage adjustments), necessitates admission to a 
hospital, prolongs stay in a health care facility, necessitates supportive treatment, significantly 
complicates diagnosis, negatively affects prognosis, or results in temporary or permanent harm, 
disability, or  death (Medscape, 2016).  
2.2.12 Drug classes causing ADR 
 A review of previous journals and articles on drug classes associated with ADR shown 
several interesting trends. Certain drug classes seemed to be recurrently associated with 
ADR. The trend also related to the frequent use of a specific drug class in particular client 
groups. A systematic review showed that 60 to 70% of all ADR causing hospital admission, 
or that occurred during hospital stay, are caused by six classes of drugs: antibiotics, 
anticoagulants, cardiac glycosides, diuretics, hypoglycaemic agents and NSAIDs (Wiffen et 
al., 2002). Another recent systematic review focused on 13 papers and confirmed that more 
than 50% of preventable drug-related admissions are caused by four drug groups: 
antiplatelets, diuretics, NSAIDs, and anticoagulants (Howard et al., 2007).  
Davies and colleagues summarized that the same drug types (antibiotics, diuretics, cardiac 
glycosides, and hypoglycaemic agents) have been linked to ADR since 1960 in hospitalized 
patient studies with no noticeable changes, except in special patient groups (Davies et al., 
2007). Diuretics were prevalent in elderly clients whereas NSAIDs and opiates were 
commonly identified in surgical patient studies. Clearly, necessary action should be taken as 
similar drug classes are producing pharmacologically predictable ADR over decades.  
2.2.13 ADR and specialized clinical setting 
 Review papers published have confirmed that most ADR studies were conducted in general 
medical units, which made direct comparison difficult (Davies et al., 2007). Factors such as 
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the number of drugs prescribed and diagnosis of clients might be contributing causes, rather 
than the clinical setting into which the patients were admitted.  
2.2.14 Preventing ADR  
As significant proportions of ADR are considered preventable or avoidable, the logical 
approach in improving client care and reducing the occurrence of ADR is to focus on this 
element. The strategies in preventing ADR can be distributed into two main approaches; by 
focusing on the process of care and also by highlighting patients at risk, so that appropriate 
intervention can be tailored to prevent the occurrence of ADR.  
The first approach which focuses on process of care adopts that the occurrences of adverse 
drug events are followed by the occurrence of errors. Therefore, any actions that can be 
implemented to avoid error could directly prevent unwanted events. This concept is based 
on the Reason's Swiss cheese model of system failures, which describes the important role 
of system defenses (Reason, 2000).  This model also explains the way these barriers, which 
are represented by aligned slices of Swiss cheese, can be breached by an error. 
In the second approach, individual features are utilized to predict and highlight their risk. In 
such cases, implementation of individualized intervention could prevent the occurrence of 
ADR. A risk stratification model to identify patients at risk for ADR is an example in this 
approach. 
2.2.14.1 Process of care 
 As mentioned earlier preventing ADR using a process of care approach uses characteristics 
that differentiate preventable ADR with non-preventable ADR.  An ADR is considered 
preventable if it involves inappropriate prescribing including, misuse, overuse, or underuse 
of medications, inappropriate dosing, allergy reporting and monitoring (Pham and Dickman, 
2007). So, strategies that target appropriate medication use at any stage of the drug use 
process can be exploited to reduce ADR occurrences. For example, built-in computer 
programmes with electronic prescribing databases, greater pharmacist involvement in 
patient care, and spontaneous reporting systems can improve communication and interaction 
between healthcare professionals and or patients which might help to highlight inappropriate 
prescribing and minimize the occurrence of ADR. 
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2.2.14.1.1 Utilizing computer systems  
One of the methods being broadly used in the US, and being proposed for adoption by the 
UK, is the application of computerized systems in healthcare.  Computerized systems can be 
introduced into different stages of the drug use process in order to reduce the probability of 
medication error, which could lead to the occurrence of ADR. Therefore, electronic patient 
information systems can help to prevent such an error from occurring. Furthermore, 
information technology can also be used to improve communication, making information 
accessible, prompting for information, helping with calculation, checking and monitoring 
decision support. 
 Computerized Physician Order Entry (CPOE) with Clinical Decision Support System 
(CDSS) are two types of intervention that have shown benefits beyond medication safety, 
although it has its own limitations (Rommers et al., 2007).  CPOE is a computerized system 
where the prescriber will perform medication order online, using computer programmes.  
CDSS is a system used to provide computerized advice while prescribing and usually works 
in conjunction with CPOE. CDSS has the ability to execute automatic drug allergy checks, 
drug interactions and also advice on drug dose and routes. A review of five studies conducted 
by Kaushal and colleagues highlighted the potential of these systems to reduce medication 
error (Kaushal et al., 2003).  
There are studies that have shown the benefits of a computer–based monitoring system with 
an alert in detecting adverse drug events (Rommers et al., 2007). However, there was not 
enough evidence available to show these interventions could reduce the occurrence of ADR 
(Kaushal et al., 2003). 
2.2.14.1.2 Pharmacy intervention 
 Proactive intervention such as pharmacy-led intervention may likewise help in preventing 
ADR, due to their expertise and knowledge of pharmacology and the side effects of 
medications. Pharmacists participating in ward rounds, medication reconciliation or 
pharmacy-led medication reviews, and community pharmacist intervention, are examples of 
strategies that can be engaged to prevent the occurrence of ADR.  
 In a meta-analysis of 32 studies to determine the effects of pharmacist-led medication 
reviews conducted in older clients, Holland et al (2008) finished that pharmacist intervention 
increased the knowledge and adherence of clients. Yet, no evidence of beneficial effects on 
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hospital admission and deaths was noticed, partly due to the suboptimal design of many 
studies.  
A randomized controlled study focusing on clients more than 80 years old has showed that 
pharmacist intervention can lead to major reduction in morbidity and costs of care (Gillespie 
et al., 2009). This study was conducted in Sweden.  Four hundred patients were randomized 
into control (n=201) and interventions (n=199) groups. The control group received standard 
care without direct involvement from the pharmacist on the ward, whereas, ward-based 
pharmacists were involved in performing the interventions on the other group. Patients were 
monitored over 12-month follow-up period. There was 80% reduction in drug-related 
readmission, 47% reduction in visits to emergency departments and a 16% reduction in all 
visits to hospital. However, the time spent (average 2 hour and 20 minutes) by pharmacists 
on each patient might limit the opportunity in implementing this service in a real hospital 
setting. Perhaps, a pharmacist focusing on high risk patient group only could be a more 
practical option to tackle this problem. 
2.2.14.1.3 Spontaneous reporting and documentation  
Poor documentation on clients with a history of ADR can lead to re-exposure of the 
offending drug causing the client to experience the same ADR again. Previous occurrence 
of ADR has been shown as an important risk factor for developing ADR. Therefore, simple 
intervention, such as emphasizing the importance of accurate documentation of ADR at the 
time of reaction, and providing relevant information to the patient about ADR, can help to 
prevent further occurrence (Tangiisuran et al., 2009). 
2.2.14.1.4 Communication and other intervention 
 Improving communication between the healthcare provider and patients has revealed a 
moderate impact in reducing ADE.  For example, a significant reduction in serious ADE was 
shown in frail and elderly patients randomized to receive a comprehensive geriatric 
assessment, as compared to the usual care (Schmader et al., 2004). Communicating the 
benefits and risks of medications to patients could promote shared decision making about 
pharmaceutical need. Patient's awareness of the existence of ADR can help in its prevention.  
The introduction of new drugs, together with the large amounts of drugs available in the 
market, can increase the complexity in prescribing, especially in older patients (Spinewine, 
2007). Continuous, up to date information on new and high risk medications, including 
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information on comparative benefits, risks, and contraindication, using computerized 
systems can reduce the risk of ADR. Continuous education for healthcare professionals can 
help in preventing ADR by preventing the prescription of inappropriate medication to older 
patients. 
2.2.14.2 Highlighting patient at risk  
As compared to focusing on process of care, highlighting patients at risk of ADR can help 
in preventing ADR. Identifying individuals at high risk of developing ADR using several 
risk factors, including genetic predisposition and other clinical factors, to target 
individualized intervention are central in this approach. 
Recent advances in pharmacokinetics, especially the identification of mutation and 
polymorphisms in the genes that code for drug-metabolizing enzymes, drug transporters, and 
drug receptors, explicate the reasons behind the individual's increased risk of getting ADR 
or the increased predictability of drug response (Meyer, 2000).  
For example, genetic variants in the Thiopurine Methyltransferase (TPMT) gene have been 
linked to azathioprine-induced severe myelosuppression (Ross et al., 2007). Individuals with 
homozygosity for low activity TPMT variants (e.g. TPMT*3A) result in reduced inactivation 
of azathioprine, causing excessive accumulation of thioguanine nucleotides in hematopoietic 
tissues leading to severe or fatal myelosuppression (Ross et al., 2007). Variation in human 
genome can be considered as indicators for ADR, although high cost and lack of laboratory 
facilities to perform genotyping restrict their usage in daily clinical practice. 
2.2.14.2.1 Predicting ADR  
Preventing an event using a risk stratification approach has been successful in several areas. 
Furthermore, it is referred to as the clinical prediction model, clinical prediction rules, 
prognostic models or nomogram (Steyerberg, 2009). Risk assessment tool is another term 
which can be used interchangeably. In this approach, information (e.g. related to patients, 
disease or treatment) is drawn prospectively to stratify patients by predicting their risk of 
developing an event (Wasson et al., 1985).  
Recently, Johnston et al. (Johnston et al., 2006), attempted to isolate specific patients and 
clinical characteristics related to increased risk of experiencing adverse events (including 
ADR and medication error), using a large study sample (Johnston et al., 2006). The study 
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population (60,206) was randomly split into training and validation dataset groups. They 
found that certain age groups, diagnoses, admission sources, types of insurance and the use 
of specific medication and medication classes were associated with increased risk of adverse 
events. The retrospective nature of the study, which relied totally on voluntary reported AE, 
might limit the validity of the finding despite the availability of a huge database.  
Contrary to the previous study, Passarelli et al. developed another instrument consisting of 
three variables to predict ADR in patients more than 60 years old using a very small dataset 
(Passarelli, 2007). Only 186 patients were recruited of which 61.8% experienced an ADR. 
The variables identified were; number of drugs, number of diagnosis and the use of 
inappropriate medication, using Beer criteria. Neither internal nor external validation of the 
model was conducted, which limits the applicability of the model. 
A recent study published conducted in Germany aimed to characterize risk factors associated 
with ADR (Zopf et al., 2008). Zopf and colleagues established five variables as independent 
predictors of ADR; Increased temperature, low thrombocyte levels, low erythrocyte levels, 
multiple drug use and female sex, were identified as independent predictors of ADR. These 
risk factors were developed based on data from 907 patients with mean age of 60 years old. 
Attempts were also taken to assess the ability of the model to predict ADR, which revealed 
area under receiver operating characteristic curve of 0.80. At the maximum cut-off point the 
model reached sensitivity of 0.64 and specificity of 0.86. 
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Chapter (3) Methodology  
This chapter presents information about the methods used to apply this study. It describes 
the design of the selected approach (methodology), the sample selection and sampling 
methods, the data collection and data analysis methods. Description of the piloting stage, in 
addition the study period and the response rate are illustrated. Information about the study 
instrument, its reliability and validity preceded the study limitations which appear at the end 
of this chapter. 
3.1 Study design 
The design of this study is mixed methods one, in which data has been triangulated 
(quantitative and qualitative). The quantitative data collected by conduction a retrospective 
cross sectional approach. The quantitative data examined the compliance of the UNRWA-
PHC health providers in GS with the ADR precautions, as well as it measures specific 
indicators that reflect the prescribing practices of the UNRWA-PHC health providers and 
their compliance with the ADR precautions.  Cross sectional design is a useful for descriptive 
analysis.  It is less expensive and enables the researcher to meet the study objectives in short 
time.  It also studies the cause and effect at the same point of time and thus provides some 
possible indications about causation relationships (Burns and Grove, 1997). The qualitative 
data collection involved in-depth interviews with physicians and focus group discussions 
with elderly patients. Focus groups are facilitated group discussions using guided questions 
that are generally populated by a homogenous audience of interest to the researcher. In most 
cases (including this one), focus group studies are qualitative in nature. Qualitative data 
reveal wide range of perspectives and opinions 
3.2 Study population 
For qualitative design, the researcher included the UNRWA-PHC physicians who are 
working at the time of data collection in the selected 10 UNRWA-PHC clinics in five Gaza 
governorates. Also the researcher included the elderly patients above 60 years and follow at 
non communicable disease unit. 
For quantitative study, the researcher included prescription drugs of older people, 
representing a mix of health problems and included at least 5 drugs which a count 694 
prescriptions.  
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3.3 Sample size  
Since the target population of the study consists of two-type of populations (physicians and 
patient prescriptions). The first was a physician’s working in the selected UNRWA-PHC 
clinics in GS. The second sample included 694 prescriptions randomly selected, 48 records 
from North Governate., 229 records from Gaza Gov., 122 records from Dier Al Balah Gov., 
174 records from Khan Younis Gov., and 121 records from Rafah Gov.  
3.4 Eligibility criteria 
3.4.1 Inclusion criteria 
 Quantitative study, prescriptions for older people aged 60 years and above, both males 
and females, which has five drugs or more. 
 Qualitative study, the focus group participants was elderly patients; they selected 
purposefully from UNRWA-PHC’s. Each focus group composes on average of 7 
participants. In addition to in-depth interviews with three physicians; they selected 
purposefully from front line health providers at UNRWA-PHC’s.  
3.4.2 Exclusion criteria 
Subjects who are not eligible to be participant in the study include: 
 Prescriptions having less than five drugs prescription 
 Any prescription for client less than 60 years 
3.5. Sampling technique:  
3.5.1. Quantitative data 
According to the availability of the electronic system within UNRWA’s PHC centers, the 
researcher in cooperation with one of the UNRWA’s IT staff selected randomly all the 
available electronic records for the targeted 10 PHC centers as following: 
 Electronic medical records for elderly above 60 years who received 5 and more than 
5 drugs per prescription  
 The retrospective data must be twelve-month period prior the survey date, and if the 
necessary medical record data are too difficult or time consuming to extract, the list 
should cover as much of the study period as possible (WHO, 1993).  Given that, the 
study conducted in all the Gaza governorates and the availability of electronic 
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records, the interval of 6 months was feasible because the electronic records not 
installed in the whole of UNRWA-PHC centers. The records fall in the whole period 
of the study from July till December 2014 
3.5.2. Qualitative data 
The researcher conducted three in-depth interviews with health providers across the Gaza 
governorates to assess prescriptions practices among UNRWA’s front line health providers 
and managers (according to UNRWA system, PHC’s managers selected from the front line 
health doctors, and they have mixed duties in management and health provision) (Annex 4). 
Three focus groups discussions with elderly patients’ age more than 60 years and 
prescription have 5 drugs and more which selected purposefully; it involved both male and 
females from different age groups (Annex 5).  
3.6 Study setting 
This study was carried out in UNRWA-PHC centers at five Gaza governorates including: 
North Gaza Governorate, Gaza Governorate, Deir Al-Balah Governorate, Khan-Yunis 
Governorate and Rafah Governorate. 
3.7 Study Period 
The study is extended for 21 months; it started in December 2014 and be completed by 
October 2016.  
3.8 Ethical Considerations 
The study respected the internationally recognized research ethical and administrative 
principles.  The researcher obtained an ethical approval from Helsinki committee (annex 6).  
In addition, administrative approval was obtained from both Al-Quds University and 
UNRWA Head Quarter-Health Department.  Study participants were informed about the aim 
and procedure of the study.  
 
3.9 Study instrument 
3.9.1 Quantitative Instrument 
The researcher depends on Medscape drug checker service for category the ADRs.  
Medscape is the leading online global destination for physicians and healthcare professionals 
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worldwide, offering the latest medical news and expert perspectives; essential point-of-care 
drug and disease information; and relevant professional education (Einerson, 2011). The 
Medscape drug checker service categories the reaction into two classifications; significant 
and significant & serious. Also the researcher will collect data from the elderly medical 
records. Medical record has several parts mainly to be extracted:   
 Demographic information: such as, age, sex, and place of residence. 
 Medical history: such as DM, HTN, DM & HTN, and other diseases  
 The number of drugs taken by each clients 
 The name of drugs by each clients 
 The duration of drugs taken by each clients 
3.9.2 Qualitative tools:  
The researcher conducted three in-depth interviews with NCD physicians. In-depth 
interviews guiding questions prepared; it validated by researchers and technical experts. In 
addition to three focus groups’ discussion with elderly patients. 
3.10 Scientific rigor 
3.10.1 Content validity 
The validity was carried out for qualitative part. First, a peer check was done through health 
experts to revise the in-depth interviews guiding questions (Annex 7). The purpose of 
content validity was to assess the relevance and the appropriateness of the in-depth 
interviews guiding questions.  Feedback and comments from experts was incorporated into 
a revised version of the guiding questions. In addition, recording the in-depth interviews 
enhanced tracking up information and re-checks the accuracy of the transcripts. 
 3.10.2 Reliability 
For assuring instruments reliability during review of medical records; the researcher doing 
the following steps: begin data entry at the same day of the data collection. This step 
minimizes possible errors by checking the quality of the data. After that, the researcher re-
entry of 5% of the data after finishing data entry for assures a correct entry procedure and 
decrease entry errors. 
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3.11 Data collection 
The researcher review elderly medical records at the study settings. In other side, the 
researcher was conducted the in-depth interviews with health providers in the UNRWA 
clinics.  
3.12 Data entry and analysis: 
The questionnaires were over viewed at first followed by data entry to the Statistical Package 
for Social Sciences version 21 (SPSS Inc., Chicago, IL, USA) by the researcher himself.  
The coded variables entered into the computer.  Data cleaning was conducted to check for 
any missing or error data during entry (through running frequency analysis).   
Many different statistical tests were used, through frequency of the study factors and 
description of the study population.  Analysis included frequency tables, cross tabulations, 
and coding of data to disseminate the study factors.  A Chi-square test and independent 
sample t-test were used to investigate the relationships between the independent study 
variables and number of prescribed drugs at UNRWA-PHCs.   
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Chapter (4) Results and discussion  
This chapter presents the core results of the study in illustrated and organized tables and 
graphs in a comparative way; it shows the descriptive analysis for included sample to reflect 
the real situation of elderly in the PHC centers at UNRWA. Furthermore, it includes the 
relationships between selected studied variables concerning polypharmacy. 
4.1 Characteristics of the study population 
4.1.1 Profile of the study population  
Table (4.1): Distribution of study participants by gender, age and governorates 
Variable  N % 
Gender  
Male 265 38.2 
Female 429 61.8 
Total  694 100.0 
Age                                                                           
Less than 65 years 237 34.1 
From 65 – 69 years 189 27.2 
From 70 to 74 years  121 17.4 
75 Years and above  147 21.2 
Total 694 100.0 
Mean = 68.87 , Median = 67.00 , Std = 7.20 
Governorate   
North  48 6.9 
Gaza 229 33.0 
Middle  122 17.6 
Khanyounis 174 25.1 
Rafah  121 17.4 
Total  694 100.0 
Primary Health Care 
Beach 48 6.9 
Dair Albalah 72 10.4 
Japaneas 50 7.2 
Khanyounis 124 17.9 
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Nuseirate 50 7.2 
Al Rimal 125 18.0 
Saftawi 48 6.9 
Shaboura 58 8.4 
Shaikh Radwan 56 8.1 
Shouka 63 9.1 
Total 694 100.0 
 
The following table describes the personal characteristics of the study population. The study 
participants consisted of 694 patients attending UNRWA PHCs in Gaza governorates, of 
them 265 (38.2%) were males and 429 (61.8%) were females’ patients, their age ranged 
between 60 – 103 years with mean age 68.78 ±7.20 years. The mean age for male was (68.36) 
years (SD: 7.21), and for female was (69.18) years (SD: 7.18). According to age groups, 
34.1% aged less than 65 years old, 27.2% aged between 65 -69 years, and 21.2% aged 75 
years and above. Patients of the age less than 65 years are the largest proportion of the study 
participants.  
In GS, elderly female represent higher proportion compared to males with higher life 
expectancy. According to PCBS (2015), life expectancy is estimated at 72.1 years in the GS 
(70.7 for males and 73.5 for female), which is consistent with the global trend, and the 
percent of older women (60 years and above) is higher than older men, with sex ratio reaches 
about 80.5 males against 100 females. 
In GS, the prevalence of chronic morbidities among older people appears to be high, as 
68.6% of older people (60 years and above) have chronic diseases (PCBS, 2015).  
Furthermore, according to UNRWA reports, clients aged 40 years old and above represented 
91% of all clients who utilized services of the NCD clinics within the PHCs, and out of them 
65 % of patients were female (UNRWA, 2012). 
Finding also showed that 48 (6.9%) of study participants were from the North governorate 
from al saftawi clinic, 229 (33.0%) were from Gaza governorate from ( AL Rimal, Al Shaikh 
Radwan and beach) clinics, 122 (17.6%) were from the Middle governorate from ( Al 
Nuserirat and Dair Al Balah) clinics, 174 (25.1%) were from Khanyounis governorate from 
( Japanese and Khanyounis) clinics , and 121 (17.4%) were from Rafah governorate from 
(Shouka and Shaboura) clinics. As shown in the figure 4.1, the largest proportion was from 
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Gaza because it is the biggest governorate and it was represented by three HCs, while North 
Gaza was the lowest proportion because it was represented by one HC. 
 
Figure 4.1 Distribution of study participant's governorates 
4.2 Health profile of the study population. 
4.2.1 Chronic morbidity 
Table (4.2): Distribution of study participants by chronic morbidity 
Health problem N % 
Diabetes & Hypertension 365 52.6 
Diabetes mellitus 2 40 5.8 
Hypertension 244 35.2 
Other diseases    45 6.5 
Total  694 100.0 
 
Table (4.2) showed that Diabetes & Hypertension presented the highest prevalence among 
elderly accounted for 365 (52.6%) of study participants, followed by Hypertension 
accounted for 244 (35.2%), Diabetes mellitus 2 accounted for 40 (5.8%), and 45 (6.5%) had 
other disease. Our findings are in accordance with the reports of the PCBS that found the 
most common disease affecting elderly is HTN, followed by DM. Similar results obtained 
from a case-control study carried out in Israel where a geriatric palliative approach and 
methodology to combat the problem of polypharmacy was introduced, assessment of the 
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case group showed 46% of the patients have HTN, and 30% of the patients have DM 
(Garfinkel, Zur-Gil and Ben-Israel, 2007). 
In addition, previous report by UNRWA indicated that the main health problems among 
elderly are HTN with a 44.5% of the total registered patients and combination of HTN and 
DM with a 38.2% of total registered patients (UNRWA, 2012). 
Table (4.3): Distribution of study participants by chronic morbidity and gender 
Gender Male Female Total 
Health problem Nu. % Nu. % Nu. % 
Diabetes & Hypertension 121 45.7 244 56.9 365 52.6 
Diabetes mellitus 2 20 7.5 20 4.7 40 5.8 
Hypertension 93 35.1 151 35.2 244 35.2 
Other diseases    31 11.7 14 3.3 45 6.5 
Total  265 100.0 429 100.0 694 100.0 
 
Table (4.3) showed that among male patients, 121 (45.7%) had Diabetes & Hypertension, 
20 (7.5%) had Diabetes mellitus, 93 (35.1%) had Hypertension, and 31 (11.7%) had other 
disease. Among Female patients, 244 (56.9%) had Diabetes & Hypertension, 20 (4.7%) had 
Diabetes mellitus, 151 (35.2%) had Hypertension, and 14 (3.3%) had other disease.  
Table (4.4): Distribution of study participants by chronic morbidity and age 
Age group Less 65 65 – 69 70-74 75 and 
above 
Total 
Health 
problem 
Nu. % Nu. % Nu. % Nu. %   
Dia etes & 
Hypertension 
141 59.5 103 54.4 59 48.8 62 42.2 365 52.6 
Diabetes 
mellitus 2 
22 9.3 14 7.4 4 3.3 0 0.0 40 5.8 
Hypertension 67 28.3 57 30.2 51 42.1 69 46.9 244 35.2 
Other diseases    7 3.0 15 7.9 7 5.8 16 10.9 45 6.5 
Total  237 100.
0 
189 100.
0 
121 100.
0 
147 100.
0 
694 100.
0 
 
Table (4.4) showed that among patients aged less than 65 years, 141 (59.5%) had Diabetes 
& Hypertension, 22 (9.3%) had Diabetes mellitus, 67 (28.3%) had Hypertension, and 7 
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(3.0%) had other diseases. Among patients aged between 65 -69 years, 103 (54.4%) had 
Diabetes & Hypertension, 14 (7.4%) had Diabetes mellitus, 57 (30.2%) had Hypertension, 
and 7 (5.8%) had other diseases. Among patients aged 70-74 years, 59 (48.8%) had Diabetes 
& Hypertension, 4 (3.3%) had Diabetes mellitus, 51 (42.1%) had Hypertension, and 7 (5.8%) 
had other diseases. Among patients aged 75 years and above, 62 (42.2%) had Diabetes & 
Hypertension,, 69 (46.9%) had Hypertension, and 16 (10.9%) had other diseases . 
This result indicated that more than half of the patients were between 60 – 69 years old, the 
most prevalent disease was Diabetes & Hypertension with a rate of 52.6%, followed by 
Hypertension with a rate of 35.2%. 
It is obvious to say that patients over 65 years old are more likely to have several chronic 
disorders, each requiring at least one medication (Zahn et al., 2001). Furthermore, elderly 
patients with more than one health illness are likely to receive care from several healthcare 
providers, each of whom may prescribe a different medication to treat the same symptoms 
(Conry, 2000).   
Table (4.5): Distribution of study participants by chronic morbidity and governorate 
Governorate        
Diabetes & 
Hypertension 
Diabetes 
mellitus 2 
Hypertension Others Total 
N % N % N % N % N % 
North  30 62.5 4 8.3 13 27.1 1 2.1 48 6.9 
Gaza 120 52.4 15 6.0 76 33.2 18 7.9 229 33.0 
Middle  73 59.8 7 5.7 36 29.5 6 4.9 122 17.6 
Khanyounis 88 50.6 8 4.6 64 36.8 14 8.0 174 25.1 
Rafah  54 44.6 6 5.0 55 45.5 6 5.0 121 17.4 
Total 365 52.6 40 5.8 244 35.2 45 6.5 694 100.0 
 
 
Analysis of chronic morbidity in each governorate showed that in North governorate 30 
(62.5%) of patients had Diabetes & Hypertension, 4 (8.3%) had Diabetes mellitus, 13 
(27.1%) had Hypertension, and 1 (2.1%) had other diseases. In Gaza governorate 120 
(52.4%) of patients had Diabetes & Hypertension, 15 (6.0%) had Diabetes mellitus, 76 
(33.2%) had Hypertension, and 18 (7.9%) had other diseases. In Middle governorate 73 
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(59.8%) of patients had Diabetes & Hypertension, 7 (5.7%) had Diabetes mellitus, 36 
(29.5%) had Hypertension, and 6 (4.9%) had other diseases. In Khanyounis governorate 88 
(50.6%) of patients had Diabetes & Hypertension, 8 (4.6%) had Diabetes mellitus, 64 
(36.8%) had Hypertension, and 14 (8.0%) had other diseases. In Rafah governorate 54 
(44.6%) of patients had Diabetes & Hypertension, 6 (5.0%) had Diabetes mellitus, 55 
(45.5%) had Hypertension, and 6 (5.0%) had other diseases. This result indicated that 
Diabetes & Hypertension was the most common chronic morbidity, and the highest rates 
were in Gaza and Khanyounis governorates. The second chronic morbidity was 
Hypertension and the highest rate was in the Gaza and Middle zone governorates.  
Through 22 PHCs, UNRWA provides health-care services to the vast majority of the over 
1.2 million Palestine refugees in GS. The number of patients with NCDs is increasing 
consistently by approximately 5% per year, and this has resulted in financial challenges to 
UNRWA. Expenditure on drugs is high and UNRWA spend between 17 – 18 million USD 
for drug dispensing per year. In 2010, 42% of drug expenditure was spent on drugs for the 
treatment of DM and CVDs (UNRWA, 2016), and 41% of total drug expenditure in 2014 
(UNRWA, 2014), and 46% of total drug expenditure in 2015 (UNRWA, 2015).     
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4.3 ADR among older people  
4.3.1 Number of drugs prescribed 
Table (4.6): Distribution of study participants by number of drugs prescribed 
Number of prescribed drugs N % 
5  203 29.3 
6 171 24.6 
7 132 19.0 
8 and more 188 27.1 
Total  694 100.0 
Mean = 6.78 , Median = 6.00 , Std = 1.88 
 
Table (4.6) showed that 203 (29.3%) of prescriptions contain 5 drugs, 171 (24.6%) had 6 
drugs, and 132 (19.0%) had 7 drugs and 188 (27.1%) had 8 and more. This result reflected 
high rates of prescribed drugs for individual patients, and this result raised the need for 
rational prescription of drugs in UNRWA health centers. During the in-depth interviews with 
NCDs physicians, all of them said that “Because of all elderly patients who follow in NCDs 
have more than one chronic disease, so they need many drugs for chronic disease itself in 
addition to others medication for acute illness such as paracetamol, trufen, and anti-
bacterial drug”. Here, the researcher recommends to use optimal of drugs dispensed for the 
elderly and how to reduce them, taking into account patient’s morbidity and not the patients 
request, in addition to change of analgesics prescribing behavior by reinforcement of the 
knowledge of the adverse effects of different analgesics and the availability of relatively 
safer alternatives. 
Among the prescriptions included in this study, the minimum number was 5 drugs and the 
maximum number was 16 drugs, with a mean number of drugs per prescription was 6.78 
drug and SD= 2.15. There is no published data yet regarding polypharmacy in GS in order 
to compare these results. In other countries, they used the measurement mean number of 
medications used.  
Medically, inappropriate and economically inefficient use of drugs is widely encountered in 
many countries both in health facilities and in the communities, jeopardizing the quality of 
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care and draining the limited resources for health. The existence of this public health problem 
and the need for action has been acknowledged worldwide (WHO/WPRO, 2002). 
In the USA, it has been estimated that 20% of Medicare beneficiaries have 5 or more chronic 
conditions and 50% receive 5 or more medications (Tinetti et al., 2004).  Also, among 
ambulatory older adults with cancer, 84% were receiving 5 or more medications and 43% 
were receiving 10 or more medications (Nightingale et al., 2015). Recent study conducted 
in Finland a study assessed changes in medicine use and polypharmacy, two cross-sectional 
surveys were carried out among community dwelling persons aged 65 years or over in 1990-
1991 (n = 1,131) and 1998-1999 (n = 1,197), the study found that the mean number of 
medications used per elderly person grew from 3.1 in 1990-1991 to 3.8 in 1998-1999 
(Linjakumpu et al., 2002).  
Studies conducted in Palestine regarding patterns of prescribing reflected that the number of 
prescribed drugs per prescription was within WHO standards (< 2.0 drugs per prescription). 
The number of drugs was 2.7 drug per prescription (El Baba, 2012), 1.9 per prescription 
(Khatib, et al., 2008), 1.92 drugs per prescription (Fattouh, 2005), 2.55 drug per prescription 
(Obeidalla, 2000).  Our study showed that mean number of medications used was 7.8. In our 
study the mean number of medications is higher than that of previous local studies, and this 
might be due to pattern of prescribing medication by physicians and may related to inclusion 
criteria with prescriptions that have more than five drugs. 
4.3.2 Prevalence of ADR among older people  
The researcher depends on Medscape drug checker service for category the ADRs.  
Medscape is the leading online global destination for physicians and healthcare professionals 
worldwide, offering the latest medical news and expert perspectives; essential point-of-care 
drug and disease information; and relevant professional education (Einerson, 2011). 
Medscape provides many health services and tools; of them drug interaction checker. The 
drug interaction checker service does not endorse drugs, diagnose patients, or recommend 
therapy. The Service is an informational resource designed to assist licensed healthcare 
practitioners in caring for their patients and provide consumers with drug specific 
information. Healthcare practitioners should use their professional judgment in using the 
information provided.  
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Table (4.7): Prevalence of ADR among older people attending UNRWA clinics 
Classification of ADR   Yes No Total 
Nu. % Nu. % Nu. % 
Minor 500 72.0 194 28.0 694 100.0 
Significant  540 77.8 154 22.2 694 100.0 
Serious 480 69.2 214 30.8 694 100.0 
Total 652 93.9 42 6.1 694 100.0 
 
The Drug Interaction Checker explains the mechanism of each drug interaction, and its 
classified the interaction into (serious, significant and minor), and in certain cases, can 
provide the recommended course of action to manage the interaction. The Drug Interaction 
Checker will also display any interactions between your chosen drugs and food (Medscape, 
2016).  A significant ADR is defined as any unexpected, unintended, undesired, or excessive 
response to a drug that requires discontinuing the drug (therapeutic or diagnostic), requires 
changing the drug therapy, requires modifying the dose (except for minor dosage 
adjustments), necessitates admission to a hospital, prolongs stay in a health care facility, 
necessitates supportive treatment, significantly complicates diagnosis, negatively affects 
prognosis, or results in temporary or permanent harm, disability, or  death. A strong or 
serious ADR is also defined as any unexpected, unintended, undesired, or excessive response 
to a drug that requires discontinuing the drug (Avoid or Use Alternate Drug) (Messcape, 
2016).  
Majority of prescriptions that included in the study shows different type of ADR as shown 
in table 4.7. An ADR was shown in 93.9% of prescriptions, 72.0% was minor ADR, 77.8% 
significant ADR and 69.2% was serious ADR from the prescriptions, meaning that ADR 
found in 93.9% of prescriptions that prescribed in UNRWA clinics (Annex 8 illustrated the 
clinical ADR between different types of drugs). Through the in-depth interviews with NCDs 
physicians they justified that “the awareness about ADRs based on the physician’s 
awareness; in addition to they respond to the client’s requests to prescribe some medications 
not related to their cases with neglecting of ADRs could be happened”. The researcher 
recommended increasing physician’s awareness regarding ADRs and drugs interaction, in 
addition to develop and encourage of interaction between health personnel especially 
physicians, pharmacists and nurses to reduce ADRs and its consequences.  
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4.3.3 The relation between number of drugs and ADR  
Table (4.8): Number of drugs caused ADR 
 Minor Significant Serious All 
Number of drugs Nu. % Nu. % Nu. % Nu. % 
5 114 56.2 121 59.6 114 56.2 193 90.1 
6 119 69.9 126 73.7 107 62.6 155 90.6 
7 96 72.7 116 87.9 95 72.0 127 96.2 
8 and above 171 91.0 177 94.1 164 87.2 187 96.5 
Total 500 72.0 540 77.8 480 69.2 652 93.9 
 
Using drug checker to examine the possibility of interaction between drugs, the results 
presented in table (4.8) showed that 540 (77.8%) of prescribed drugs had significant 
interaction, and 480 (69.2%) had serious interaction. The above table also showed that 
interaction between 5 drugs was significant in 121 (59.6%) of prescriptions, and was serious 
in 114 (56.2%) of prescriptions.  Furthermore, interaction between 6 drugs was significant 
in 126 (73.7%) of prescriptions, and was serious in 107 (62.6%) of prescriptions. In addition, 
interaction between 8 drugs and more was significant in 177 (94.1%) of prescriptions, and 
was serious in 164 (87.2%) of prescriptions. 
The use of larger numbers of drug therapies has been independently associated with an 
increased risk for an ADR, irrespective of age (Field et al., 2001), and increased risk of 
hospital admission (Lu  et al., 2015). 
The issue of ARDs and polypharmacy is not a new issue. A study carried out by Cooper 
(1996) reported that ADRs were associated with polypharmacy, and the mean number of 
drugs per patient in the ADR group was 7.8, compared with 3.3 amongst residents who did 
not experience them.  Other studies have also shown that the risk of ADR is related to the 
number of medicines taken (Carbonin et al., 1991), and that the elderly receive more 
medicines, sometimes inappropriately.  Thus, a positive correlation emerges between 
increasing age and ADR rate for some medical conditions (Dormann et al., 2001). 
In addition, using the Beers criteria have recognized that use of drugs known as 
"inappropriate" was prevalent in the US, Canada, and Europe (Fialová et al., 2005). In a 
sample of community-dwelling older adults in the US, 43% used at least one medication that 
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would be deemed potentially inappropriate (Davidoff et al., 2015).  Additional study, using 
Medicare data and the 2012 Beers criteria, showed that the point prevalence in each calendar 
month of potentially inappropriate medications used in adults ≥65 years was 34.2% in 2012 
(Jirón et al., 2016). ADRs may cause serious life hazards and are likely to be between the 
fourth and sixth leading cause of death in the USA (Lazarou, Pomeranz, and Corey, 2000). 
However, the use of too many medications can pose problems of serious ADR, and often 
can contribute to non-adherence (Hepler and Strand, 1990). 
Another study by Davies et al (2009) established numbers of medication as the only 
independent predictor of ADR that occur during hospital stay with a hazard ratio of 1.14. 
Other studies also found a like relationship (Zopf et al., 2008). Polypharmacy also increases 
drug interactions, falls, hospital admission, length of hospital stay, hospital readmission, and 
mortality (Campbell et al., 2004). 
Drugs interaction works in 2 ways: it will spoil the drugs or will increase the effect of drugs, 
and both ways may result in serious harm effects for the patients. Polypharmacy is a 
contributing factor to ADR, and to decrease the likelihood of harm effects, it is suggested to 
decrease the number of prescribed drugs and to consume drugs with adequate time spacing 
between drugs. 
Table (4.9): List of drugs caused Serious ADR: 
Drugs Type of 
Interaction 
Complication Intervention 
Aspirin+ Enalapril Serious 
 
Renal impairment Monitoring KFT , if 
deterioration happens 
then change aspirin to 
Plavix or give another 
antihypertensive 
Aspirin+ Ibuprofen Serious Renal impairment Administer ibuprofen 8 h 
before aspirin or at least 
2-4 h after aspirin. 
Enalapril+ Losartan Serious Hypotension, 
Hyperkalemia, and 
Renal impairment 
Avoid using together 
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Enalapril + 
Allopurinol 
Serious Risk of 
anaphylaxis, 
Stevens Johnson 
syndrome. 
Avoid combination, 
Periodic monitoring of 
white blood cell counts is 
recommended. 
Enalapril+( 
Ibuprofen, 
Diclofenic) 
Serious Renal impairment Adjust NSAIDs dose, 
monitor KFT 
Carbamazepine + 
Amiodarone 
Serious  Use alternative, avoid 
combination 
Carbamazepine + 
Simvastatin 
Serious Decrease drug 
effectiveness 
Avoid combination, Or 
increase the dose of 
simvastatin 
Carbamazepine + 
Colchicine 
Serious Decrease drug 
effectiveness 
Use alternative 
Carbamazepine + 
Diltiazem 
Serious Decrease drug 
effectiveness 
Avoid or Use Alternate 
Drug 
Carbamazepine + 
Hydrochlorothiazide 
Serious Increased risk of 
systemic 
hyponatremia 
Clinical monitoring of 
patient mental status and 
periodic measurement of 
serum sodium 
concentrations 
Amlodipine + 
Simvastatin 
Serious Increase risk of 
myopathy, 
rhabdomyolysis 
Limit simvastatin dose to 
no more than 20 mg/day 
Simvastatin + 
Colchicine 
Serious Increased risk of 
rhabdomyolysis 
Avoid using together, 
check the creatine kinase 
level a two after co 
administration of these 
agents 
Simvastatin+ 
Diltiazem 
Serious Increase risk of 
statin-induced 
myopathy 
Limit simvastatin dose to 
no more than 10 mg/day 
when used concurrently. 
Simvastatin+  
Amiodarone 
Serious Potential for 
increased risk of 
myopathy, 
rhabdomyolysis 
Do not exceed 
simvastatin 20 mg daily 
when given concurrently 
Atenolol + Bisoprolol Serious Increase serum 
potassium 
Use only one of the drugs 
, reach the maximum 
dose before adding the 
other drug 
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Bisoprolol + Digoxin Serious Increase the risk of 
bradycardia 
Avoid combination, 
Serum digoxin levels, 
heart rate, and blood 
pressure should be 
monitored closely 
Amiodarone + 
Digoxin 
Serious Increase serum 
digoxin 
concentrations by 
up to 70%, 
frequently 
resulting in clinical 
toxicity 
Empirical reduction of 
digitalis dosage by one-
third to one-half should 
be considered 
 
Table (4.10): List of drugs caused Moderate ADR: 
Drugs Type of 
Interaction 
Complication Intervention 
Aspirin + Atenolol Moderate Increase serum 
potassium 
Use Caution/Monitor, 
Monitor the BP , serum 
Potassium 
Aspirin + Amlodipine Moderate Increased blood 
pressure may result 
Monitoring for altered 
blood pressure control is 
recommended 
Aspirin + 
Glibenclamide 
Moderate Risk of 
hypoglycemia 
Close monitoring for the 
development of 
hypoglycemia is 
recommended 
Aspirin+  Warfarin Moderate Both increase 
anticoagulation 
Monitoring for 
excessive 
anticoagulation and 
overt and occult 
bleeding is 
recommended 
Aspirin + Digoxin Moderate may increase plasma 
digoxin 
concentrations 
Monitor for altered 
pharmacologic effects 
of digoxin and for 
increased plasma levels 
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Atenolol + 
Hydrochlorothiazide 
Moderate May increase the 
risk of 
hyperglycemia and 
hypertriglyceridemia 
in some patients 
Monitoring of serum 
potassium levels, blood 
pressure, and blood 
glucose is 
recommended during co 
administration 
Atenolol + 
Amlodipine 
Moderate Additive reductions 
in heart rate, cardiac 
conduction, and 
cardiac contractility 
may occur 
Close clinical 
monitoring of patient 
hemodynamic response 
and tolerance, and the 
dosage of one or both 
agents adjusted as 
necessary 
Atenolol + 
Furosemide 
Moderate Atenolol increases 
and furosemide 
decreases serum 
potassium. Effect of 
interaction is not 
clear 
Monitoring of serum 
potassium levels, blood 
pressure, and blood 
glucose is 
recommended 
Insulin + Metformin Moderate Co administration of 
metformin increases 
the risk of 
hypoglycemia 
associated with 
insulin. 
Close monitoring for the 
development of 
hypoglycemia is 
recommended 
Furosemide + 
Hydrochlorothiazide 
Moderate Synergistic effects 
on diuresis and 
excretion of 
electrolytes 
including sodium, 
potassium, 
magnesium, and 
chloride 
Dosages should be 
titrated slowly and 
carefully, and 
electrolytes, BUN, fluid 
status, blood pressure, 
and renal function 
should be monitored 
regularly 
Amlodipine +  
Bisoprolol 
Moderate Additive reductions 
in heart rate, cardiac 
conduction, and 
cardiac contractility 
may occur 
Close clinical 
monitoring of patient 
hemodynamic response 
and tolerance is 
recommended 
Amlodipine + 
Carbamazepine 
Moderate Decrease the plasma 
concentrations and 
pharmacologic 
effects of calcium 
channel blockers 
Caution is advised if 
CCBs must be used 
concomitantly with 
carbamazepine through 
dose adjusting 
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Simvastatin + 
Digoxin 
Moderate Simvastatin will 
increase the level or 
effect of digoxin 
Monitor the digoxin 
level and potassium 
level 
Simvastatin + 
Warfarin 
Moderate Increase the risk of 
myopathy 
If there are signs of 
myopathy , then you 
have to use another 
cholesterol  decreasing 
agents like Ezetmibe 
drug 
Digoxin + 
Hydrochlorothiazide 
Moderate hydrochlorothiazide 
increases effects of 
digoxin by 
pharmacodynamics 
synergism 
Monitor the digoxin 
level 
Digoxin +Enalapril Moderate Increased plasma 
digoxin levels may 
result 
Clinical response and 
digoxin levels should be 
monitored 
Digoxin + Metformin Moderate Digoxin is a cationic 
drug and 
theoretically could 
decrease the 
excretion of 
metformin by 
competing for renal 
tubular transport 
Reduce the metformin 
dose as necessary 
Digoxin 
+Furosemide 
Moderate Diuretic-induced 
hypokalemia and 
hypomagnesaemia 
may predispose 
patients on digoxin 
to arrhythmias. 
Digoxin, potassium and 
magnesium levels 
should be followed 
closely 
Enalapril 
+Furosemide 
Moderate Co administration 
makes hypotension 
and hypovolemia 
more likely than 
does either drug 
alone 
Monitoring of blood 
pressure, diuresis, 
electrolytes, and renal 
function is 
recommended during co 
administration 
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Enalapril + 
Glibenclamide 
Moderate Enalapril increases 
the hypoglycemic 
effect by 
pharmacodynamic 
synergism 
Close monitoring for the 
development of 
hypoglycemia is 
recommended 
Enalapril + 
Metformin 
Moderate Enalapril increases 
toxicity of 
Metformin by 
unspecified 
interaction 
mechanism 
Close monitoring for the 
development of 
hypoglycemia is 
recommended 
Losartan + Aspirin Moderate May result in renal 
function 
deterioration, 
particularly in 
elderly 
Blood pressure 
monitoring, Renal 
function should also be 
evaluated 
 
4.3.4 Most common frequent drugs prescribed at UNRWA clinics 
Table (4.11): Frequency of common prescribed drugs 
Name of drug N % 
Acetyl Salicylic Acid 100 mg (Aspirin®) 607 87.5 
Enalapril  442 63.7 
Acetyl Salicylic Acid 500mg (Paracetamol®)  412 59.4 
Insulin  367 52.9 
Atenolol  312 45.0 
Metformin  292 42.1 
Amlodipine  160 23.1 
Furosemide (Lasix®)  155 22.3 
Atorvastatin  126 18.2 
Glibenclamide  59 8.5 
Digoxin  44 6.3 
 
Table (4.11) showed that Aspirin was the highest drug prescribed as it was found in 607 
(87.5%) of prescriptions, followed by Enalapril found in 442 (63.7%) of prescriptions, and 
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Paracetamol found in 412 (59.4%) of prescriptions, while the lowest included digoxin found 
in 44 (6.3%) of prescriptions, Glibenclamide found in 59 (8.5%) of prescriptions. This result 
indicated that drugs used to treat HTN were the highest prescribed drugs, which is in 
accordance with prevalence of HTN as the most common among chronic morbidities.  
Several factors contribute to the appropriateness and overall quality of drug prescribing. 
These factors comprise avoidance of inappropriate medications, appropriate use of indicated 
medications, monitoring for side effects and drug levels, avoidance of drug-drug 
interactions, and involvement of the client and integration of client values (Spinewine et al., 
2007). From our experience, physicians sometimes prescribe some medication not related to 
the medical complain of patients, but they prescribe them to satisfy the patient. In addition, 
because drug dispensing is free (no pay) in UNRWA HCs, so many patients ask the physician 
to write special medication in the prescription because they want it for themselves or for 
their relatives. 
Polypharmacy is common in the elderly and frequently identified as an independent 
predictor of ADR. Two studies were conducted in nursing home residents revealed a positive 
correlation between the use of ≥9 scheduled medication and the risk of ADR (Field et al., 
2001; Nguyen et al., 2006). Furthermore, the relationship between drug interaction and ADR 
was mentioned by Davies et al. (2009) who reported that 59% of the total ADR identified in 
their study were linked with drug interaction, of which, 91.7% were classified as 
pharmacodynamics interactions and 5.3% pharmacokinetic in origin and the remaining 3% 
due to mixed mechanism.   
Certain drug classes seem to be recurrently associated with ADR. A systematic review 
showed that 60 to 70% of all ADR causing hospital admission, or that occurred during 
hospital stay, are caused by six classes of drugs: antibiotics, anticoagulants, cardiac 
glycosides, diuretics, hypoglycemic agents and NSAIDs (Wiffen et al., 2002). Another 
systematic review confirmed that more than 50% of preventable drug-related admissions are 
caused by four drug groups: antiplatelet, diuretics, NSAIDs, and anticoagulants (Howard et 
al., 2007). Moreover, Davies et al (2007) summarized that the same drug types (antibiotics, 
diuretics, cardiac glycosides, and hypoglycemic agents) have been linked to ADR since 1960 
in hospitalized patients. Diuretics were prevalent in elderly clients whereas NSAIDs and 
opiates were commonly identified in surgical patient studies. Clearly, necessary action 
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should be taken as similar drug classes are producing pharmacologically predictable ADR 
over decades. 
In addition, the cost of inappropriate use of drugs is enormous in terms of both scarce 
resources and the adverse clinical consequences of therapies that may have real risks but no 
objective benefits (Shankar et al., 2002) and it has been estimated that 50% or more medicine 
expenditure is being wasted through irrational prescribing, dispensing and patient use of 
medicine (Euro Health Group and WHO Collaboration, 1997). 
4.4 In-depth interview- Protocols and prescription behavior with NCD physicians 
In regard to drugs protocols and physician’s prescription behavior, the researcher developed 
several questions. Firstly the researcher asks the physicians about availability of regular 
evaluation system in UNRWA-PHCs. All of them said that “there is no regular evaluation 
system for drug management in their clinics”. When ask physicians that your clinic ever 
carried out an evaluation of your prescribing practices, all of them said that “the evaluation 
of drug management based on needs (if there are a problem happened) like clients claims, 
side effects of the usage of drugs”. Regarding written protocol for drug prescription in clinic, 
and source of protocol, all of physicians said that “UNRWA Formulary of Essential 
Medicine, this protocol available online for UNRWA team, included caution, precaution and 
contraindications usage of drugs” and when ask them about using it they tell “the usage of 
this protocol based on the doctor’s behavior”. The researcher encourages developing 
education program, training, and compliance of physician in standard treatment protocol. 
4.5 Focus Group Discussions with elderly patients 
The researcher conducted 3 focus group discussion in Gaza city, Nussirate West Camp, and 
Rafah with 23 elderly who received their health care from UNRWA PHC centers. 
Concerning the factors that may be affect on ADRs among elderly patients, the researcher 
developed five questions as following; average consultation time, average dispensing time, 
percentage of drugs actually dispensed,  percentage of drugs adequately labeled and patients' 
knowledge of correct dosage. Regarding consultation time, about 85% of elderly said that 
“the average waiting time at clinic for interview physician range between 20-40 minutes and 
them justified the long time due to increased number of reviewers. Usually the consultation 
period with physician not exceeds five minutes, this short period not affects by increase 
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reviewers number but also the reviewers themselves usually ask their doctor of urgency in 
the case that are present in the doctor room”.  
Concerning percentage of drugs adequately labeled, one participant said “I acted average of nine 
or 10 medications in the visit and the waiting a time for dispensing drug range around 10 
minutes until the disposal of the treatment and that the pharmacist does not put all the 
necessary instructions necessary only when I ask them” Another patient said that “I often 
sends one of my family members to the clinic to receive drugs at the first of each month and 
I rarely goes to the clinic”. Here the researcher endorses to improve the appropriateness of 
prescribing in elderly patients, such as training in geriatric pharmacotherapy, development 
of geriatric medicine services and involvement of pharmacist in patient care. 
In regards to patients' knowledge of correct dosage, one of the participant said in a panel 
discussion that “I know the form and color of the pill and it also I know dosage by pharmacist 
guidance”.  Another participant said that “She asks one of her family members to receive 
their medication from the clinic and she is to go to a nearby private clinic for taking the 
correct guidance for drugs dose and instructions”. With regards to its, the researcher 
endorses to develop continuous health education programs for the elderly people to raise 
their awareness about the disease, medications, and possible side effects.   
4.6 Inferential statistic 
4.6.1 Relationship between number of prescribed drugs and study variables 
Table (4.12): Relationship between number of prescribed drugs and gender 
Gender Male Female Total 
X2 Sig. 
Number of 
drugs 
Nu. % Nu. % Nu. % 
Five 92 34.7 111 25.9 203 29.3 6.733 0.081 
Six 59 22.3 112 26.1 171 24.6 
Seven 50 18.9 82 19.1 132 19.0 
Eight and above 64 24.2 124 28.9 188 27.1 
Total  265 100.0 429 100.0 694 100.0   
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Analysis of prescribed drugs among male patients indicated that 92 (34.7%) of male patients 
had 5 drugs, 59 (22.3%) had 6 drugs, and 50 (18.9%) had 7 drugs, and 64 (24.2%) had 8 and 
more. For female patients, 111 (25.9%) had 5 drugs, 112 (26.1%) had 6 drugs, and 82 
(19.1%) had 7 drugs, and 124 (28.9%) had 8 and more. This result reflected that female 
patients had higher rates of prescribed drugs compared to male patients but it's not 
significant. 
In most studies of polypharmacy, gender has been a predictor of polypharmacy. A study 
aimed to examine age-related prescription patterns in general practice found a steady 
increase in the proportion of men taking prescription drugs, while the prescribing rates for 
women decreased from the age of 70 years, and from this age there was no significant 
difference between the sexes (Nolan & O'Malley, 1987 & Nolan & O'Malley, 1988). Another 
study carried out in Sweden investigated the differences between men and women living in 
the community of Tierp and the number of prescription medications utilized reported that 
women used more medications than men, with women using an average of 4.8 prescription 
medications and men using an average of 3.8 (Johansson et al., 2001), but other studies have 
not found correlation between prescriptions and gender (Gupta et al., 1996).  
Table (4.13): Relationship between number of prescribed drugs and age 
Age Less 65 65-69 70-74 75 and above Total X2 Sig. 
Drugs 
numbe
r 
Nu. % Nu. % Nu. % Nu
. 
% Nu. % 
Five 66 27.8 65 34.4 30 24.8 42 28.6 203 29.3 17.93
2 
0.036 
Six 59 24.9 42 22.2 26 21.5 44 29.9 171 24.6 
Seven 47 19.8 25 13.2 36 29.8 24 16.3 132 19.0 
Eight 
and 
above 
65 27.4 57 30.2 29 24.0 37 25.2 188 27.1 
Total  237 100 189 100 121 100 14
7 
100 694 100   
 
 
Analysis of drug frequency for different age groups indicated that among patients aged 
between less than 65 years, 66 (27.8%) had 5 drugs, 59 (24.9%) had 6 drugs, 47 (19.8%) had 
7 drugs, and 65 (27.4%) had 8 drugs and more. Among patients aged 65-69 years, 65 (34.4%) 
had 5 drugs, 42 (22.2%) had 6 drugs, 25 (13.2%) had 7 drugs, and 57 (30.2%) had 8 drugs 
and more. Among patients aged 70 -74 years, 30 (24.8%) had 5 drugs, 26 (21.5%) had 6 
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drugs, 36 (29.8%) had 7 drugs, and 29 (24.0%) had 8 drugs and more, among patient aged 
75 and more years, 42 (28.6%) had 5 drugs, 44 (29.9%) had 6 drugs, 24 (16.3%) had 7 drugs, 
and 37 (25.2%) had 8 drugs and more. The results also indicated that there were significant 
relationship in polypharmacy related to age of patients. Different results obtained from a 
study conducted in Finland which showed that polypharmacy increases with advancing age 
and 97% of elderly over 84 years use more than 5 medications (Linjakumpu et al., 2002).   
Table (4.14): Relationship between number of prescribed drugs and governorate 
Drugs 
number 
Five Six Seven Eight and 
more 
Total 
X2 Sig. 
Govern
orates 
Nu. % Nu. % Nu. % Nu. % Nu. % 
North 
Gaza 
10 4.9 14 8.2 9 6.8 15 8.0 48 6.9 24.46
2 
0.01
8  73 36.0 57 33.3 47 35.6 52 27.7 229 33.0 
Middle 26 12.8 33 19.3 20 15.2 43 22.9 122 17.6 
Khanyo
unis 
42 20.7 44 25.7 35 26.5 53 28.2 174 25.1 
Rafah  52 25.6 23 13.5 21 15.9 25 13.3 121 17.4   
Total  203 100 171 100 132 100 188 100 694 100   
 
Table (4.14) showed that among patients from North governorate, 10 (4.9%) had 5 drugs, 14 
(8.2%) had 6 drugs, 9 (6.8%) had 7 drugs and 15 (8.0%) had 8 drugs and more. Among 
patients from Gaza governorate, 73 (36.0%) had 5 drugs, 57 (33.3%) had 6 drugs, 47 (35.6%) 
had 7 drugs and 52 (27.7%) had 8 drugs and more. Among patients from Middle governorate, 
26 (12.8%) had 5 drugs, 33 (19.3%) had 6 drugs, 20 (15.2%) had 7 drugs and 43 (22.9%) 
had 8 drugs and more. Among patients from Khanyounis governorate, 42 (20.7%) had 5 
drugs, 44 (25.7%) had 6 drugs, 35 (26.5%) had 7 drugs and 53 (28.2%) had 8 drugs and 
more. Among patients from Rafah governorate, 52 (25.6%) had 5 drugs, 23 (13.5%) had 6 
drugs, 21 (15.9%) had 7 drugs and 25 (13.3%) had 8 drugs and more. 
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Table (4.15): Relationship between number of prescribed drugs and disease 
Drugs 
number 
Five Six Seven Eight and 
more 
Total 
X2 
Sig
. Diseases Nu. % Nu
. 
% Nu
. 
% Nu. % Nu. % 
Other 
diseases    
23 11.3 13 7.6 4 3.0 5 2.7 45 6.5 99.99
8 
0.0
00 
Diabetes 
& 
Hyperten
sion 
71 35.0 69 40.4 75 56.8 
150 79.8 365 52.6 
Diabetes 
mellitus 
2 
13 6.4 13 7.6 5 3.8 9 4.8 40 5.8 
Hyperten
sion 
96 47.3 76 44.4 48 36.4 24 12.8 244 35.2 
Total  203 100 17
1 
100 13
2 
100 188 100 694 100   
 
Examining the number of prescribed drugs in relation to disease, the results showed that 
among Diabetes & Hypertension patients, 71 (35.0%) had 5 drugs, 69 (40.4%) had 6 drugs, 
and 75 (56.8%) had 7 drugs, 150 (79.8%) had 8 drugs and more. Among Diabetes mellitus 
patients, 13 (6.4%) had 5 drugs, 13 (7.6%) had 6 drugs, and 5 (3.8%) had 7 drugs, 9 (4.8%) 
had 8 drugs and more. Among Hypertension patients, 96 (47.3%) had 5 drugs, 76 (44.4%) 
had 6 drugs, and 48 (36.4%) had 7 drugs, 24 (12.8%) had 8 drugs and more. This result 
revealed that patients with Hypertension had the highest number of drugs in their 
prescriptions.   
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4.6.2 Relationship between ADRs and study variables 
Table (4.16): Relationship between ADRs and gender 
Gender Minor Significant Serious All 
Nu. % Nu. % Nu. % Nu. % 
Male 182 36.4 189 35.0 183 38.1 244 37.4 
Female 318 63.6 351 65.0 297 61.9 408 62.6 
Total 500 72.0 540 77.8 480 69.2 652 93.9 
Chi Square 2.413 10.455 0.002 2.644 
Sig. 0.072 0.001 0.513 0.073 
 
Examining the ADR in relation to gender, the results showed that among male patients 
indicated that 182 (36.4%) of male patients had Minor drug reactions and 189 (35.0%) had 
significant drug reactions while 183 (38.1%) had serious drug reactions and 244 (37.4%) of 
male patient had a drug reaction. About female patients, 318 (63.6%) of them had Minor 
drug reactions and 351 (65.0%) had significant drug reactions while 297 (61.9%) had serious 
drug reactions and 408 (62.6%) of fame patient had a drug reaction. At general, this result 
reflected that female patients have higher ADRs compared to male patients but the difference 
between two group not reach significant level (P value= 0.073). The researcher attributed 
high ADRs among female patients to the higher rates of prescribed drugs which observed in 
the previous table.  
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Table (4.17): Relationship between ADRs and diseases 
Gender Minor Significant Serious All 
Nu. % Nu. % Nu. % Nu. % 
Other diseases    15 3.0 20 3.7 15 3.1 28 4.3 
Diabetes & Hypertension 303 60.6 322 59.6 273 56.9 358 54.9 
Diabetes mellitus 2 31 6.2 26 4.8 12 2.5 36 5.5 
Hypertension 151 30.2 172 31.9 180 37.5 230 35.3 
Total 500 72.0 540 77.8 480 69.2 652 93.9 
Chi Square 68.386 63.289 63.709 91.775 
Sig. 0.001 0.001 0.001 0.001 
 
 
Examining the ADRs in relation to disease, the results showed that among Diabetes & 
Hypertension patients, 303 (60.6%) had Minor drug reactions and 322 (59.6%) had 
significant drug reactions while 273 (56.9%) had serious drug reactions. Among Diabetes 
mellitus patients, 31 (6.2%) had Minor drug reactions and 26 (4.8%) had significant drug 
reactions while 12 (2.5%) had serious drug reactions.  Among Hypertension patients, 151 
(30.2%) had Minor drug reactions and 172 (77.8%) had significant drug reactions while 480 
(69.2%) had serious drug reactions.  The variation between disease group and ADRs reach 
significant level (P value- 0.000).  
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Table (4.18): Relationship between ADRs and residence 
Gender Minor Significant Serious All 
Nu. % Nu. % Nu. % Nu. % 
North Gaza 40 8.0 37 6.9 37 6.9 47 2.4 
Gaza 161 32.2 181 33.5 181 33.5 213 32.7 
Middle 91 18.2 99 18.3 99 18.3 116 17.8 
Khanyounis 127 25.4 133 24.6 133 24.6 164 25.2 
Rafah 81 16.2 90 16.7 90 16.7 112 17.2 
Total 500 72.0 540 77.8 480 69.2 652 93.9 
Chi square 5.415 2.017 6.598 2.395 
Sig. 0.247 0.733 0.159 0.664 
 
 
Analysis of morbidity in each governorate showed that Minor, significant and serious 
reactions observed high in Gaza city followed by Khanyounis and the lowest was observed 
in North Gaza followed by Rafah. The difference between groups not reach significant level 
(P value= 0.493). The researcher attribute this finding to that the behavior prescription of 
physician at UNRWA clinics are the same.  
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Chapter (5) Conclusion and Recommendations   
This chapter provides the main conclusion and recommendations for the key persons and 
decision makers in UNRWA to minimize the ADR among population. 
5.1 Conclusion 
Globally, the older population is growing and increasing fast. The increasing number of 
elderly and the increasing drug use among the elderly especially who have chronic disease, 
emphasizes the need to continuously monitor drug utilization in this group. This study was 
conducted to explore the issue of adverse drug reactions among older people presenting at 
UNRWA-PHCs, also this thesis aimed at identifying individuals particularly at risk of 
adverse drug reactions by using a mixed- methods approach, in which data has been 
triangulated.  
The study included; 694 prescription drugs of older people had a mix of health problems and 
included at least 5 drugs which randomly selected from ten UNRWA-PHCs computer 
database in the Gaza governorates. In addition to in-depth interviews with Non-
Communicable Disease physician (n=3) that selected randomly from three centers (Al Rimal 
clinic, West Nussirate Clinic, and Al Shoukah clinic) and three focus group discussions that 
conducted with purposely selected 23 participants.  
Finding revealed that most of patients attending UNRWA PHCs in Gaza governorates were 
females, and the mean age of them were slightly higher than male patients.  More than half 
of patient’s age aged range between 60 – 69 years and around 40% of participants live in 
Gaza and North Gaza.  
 With regard to participant’s chronic morbidity, complicated hypertension with diabetes 
mellitus was the highest prevalence among elderly, followed by hypertension. HTN & DM 
is higher among female than male patients. 
Concerning number of drugs prescribed in prescriptions, around 28% of prescriptions 
contain 8 drugs and more. And with regards to most drugs prescribed in elderly prescription, 
Aspirin was the highest drug prescribed in prescriptions, followed by Enalapril and Lasix, 
while the lowest included digoxin. 
By using drug checker to examine the possibility of adverse drug reactions between drugs, 
around 94% of prescriptions included in the study shows different types of adverse drug 
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reactions; a significant adverse drug reactions was shown in seventy eight percent of 
prescriptions, in addition to serious ADR appears in around seventy percent of prescriptions, 
while minor ADRs shows in seventy tow percent of the prescriptions; meaning that 
significant and serious adverse drug reactions found in most of the prescriptions that 
prescribed in UNRWA clinics.  
Inferential statistics in regard to number of drugs per prescription and other study variables 
show that females and hypertension respondents had elicited statistically significant higher 
adverse drug reactions than their counterparts (P value less than 0.05).   
In relationship between ADRs and other study variables, finding shows no association 
reported between ADRs and gender and residency, but the association reach significant level 
between ADRs and history of disease, age and drug per prescription.  
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5.2 Recommendations 
(1) Improving physician’s awareness regarding ADRs and drugs interaction, and encourage 
interaction between health personnel especially physicians, pharmacists and nurses to reduce 
ADRs and its consequences. 
(2) Awareness and monitoring about the important role of pharmacists about rational use of drug 
through identification and documentation in the patient’s medical record of high-risk patients 
and adjusting doses in appropriate patients. 
(3) Engagement of pharmacists in the development, maintenance, and ongoing evaluation of 
ADR programs at UNRWA.  
(4) Improvement the appropriateness of prescribing in elderly patients, such as training in 
geriatric pharmacotherapy, development of geriatric medicine services and involvement of 
pharmacist in patient care. 
(5) Development continuous health education programs for the elderly people to increase 
their awareness about the disease, drugs, and possible side effects. 
(6) Use optimal of drugs dispensed for the elderly and how to reduce them, taking into 
account patient’s morbidity. 
5.3 Recommendations for new area of research  
(1) Knowledge, Attitude, and Practice of Health Care Providers at UNRWA about 
Prescription Behavior.  
(2) Evaluation and Development of UNRWA Electronic System regarding Prescribing 
Policy. 
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Annexes.  
Annex (1)   Map of Palestine 
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Annex (2) UNRWA Clinics Catchment Areas 
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Annex (3) Drug Interaction Checker  
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Annex (4) Doctors Interview’s Questions 
 
Adverse Drug Reactions among Elderly Clients at UNRWA-PHC Centers 
1. Do you have a regular evaluation system for drug management in your clinic? 
2. Has your clinic ever carried out an evaluation of your prescribing practices? 
3. Did you receive feedback about your prescribing practices? If yes, what do you do with the 
feedback? 
4. Do you have written protocols to regulate the drug prescription in your clinic? 
• What is the source of protocols you have? 
• Are those protocols in use at the clinic? 
5. What do ADRs mean to you? 
6. Do you know the main classifications of ADRs? 
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Annex (5) Focus group discussions 
 
 
Adverse Drug Reactions among Elderly Clients at UNRWA-PHC Centers 
Focus Group Discussion  
WHO Patients Care Indicators: 
1. Average consultation time 
2. Average dispensing time 
3. Percentage of drugs actually dispensed 
4. Percentage of drugs adequately labelled 
5. Patients' knowledge of correct dosage 
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  yrammuS cibarA
عة. يزداد عدد كبار الّسن بسر العالمي، الصعيد على الوفيات، معدلات وانخفاض المتوقع، العمر متوسط لزيادة كنتائج
 صلةموا إلى الحاجة على يؤّكد  مزمن، مرض لديهم الذين وخاصة استخدام الأدوية بينهم  وزيادة كبار الّسن  عدد إّن تزايد
 ينب السلبية والضارة  الدوائية التفاعلات مسألة بحث إلى الدراسة هذه هدفت. المجموعة هذه الأدوية في استخدام رصد
 إلى ا ًالأطروحة أيض هذه وتهدف  ، للأونروا التابعة الصحية الأولية الرعاية مراكز الذين يتلقون العلاج في   السن كبار
 الضارة بشكل خاص. الدوائية التفاعلات المعّرضين لخطر تحديد الأفراد
مجموعات  لاثث الدراسة وشملت. طريقة ذات أساليب متنوعة التي عالجت البيانات بطريقة حسابية مثلثّية استخدام ولقد تم ّ
 و تضمنت الوصفات الطبية صحية مختلفة  الذين لديهم مشاكل السن لكبار وصفة أدوية 496كانت عبارة عن   الأولى :
الأولية  الصحية الرعاية محوسبة خاصة بمراكز قواعد بيانات عشرة من عشوائيا ً  اختيارها تم ّ أدوية  5 عن يقل لا ما
) n=3( المعدية غير الأمراض أطباء مع مكثّفةبمقابلات  الثانية المجموعة وتمثلّت. غزة محافظات في التابعة للأونروا
 23 عم مرّكزة أجريت ثلاثة مناقشات جماعية  من تتألف الثالثة والمجموعة مراكز ثلاث من عشوائيا ً  اختيارهم تم ّ الذين
 )SSPS(البيانات  لتحليل الاجتماعية العلوم الإحصائية لبرنامج  الحزمة استخدام وتم ّ. مشاركا ًمختارين بشكل مقصود
بينما  تقلةاختبارعينة مس إلى بالإضافة والمتوسط وتحليل مجموعة البيانات الكميّة  المئوية جدولتها والنسب ذلك في بما
 تقنية موضوعية تدوينية مفتوحة  للبيانات النوعية. استخدام تم ّ
سنة ( بانحراف ) 81.96( ثللإنا الأعمار متوسط وكان الإناث، من كانوا المشاركين من ٪8.16 أن النتائج وكشفت
من  %3.16وحوالي  .) 12.7سنة ( بانحراف معياري ) 63.86( كانت لأعمار الذكور )، وبالنسبة 81.7معياري
ري  والسك  الدم ضغط كان ارتفاع للمشاركين، المزمنة بالأمراض يتعلّق وفيما ) سنة .96-60المشاركين كانت أعمارهم (
 وكان إرتفاع). ٪5.5( والسكري ،)٪3.52( ارتفاع ضغط الدميليه  ،)٪0.35( السن كبار بين انتشار نسبة أعلىمعا 
  ،)٪4.57 مقابل ٪5.05( الذكور المرضى من الإناث بين أعلى مع السكري معا الدم ضغط
من  والعدد المتوسط ،الأدوية أنواع من 5 الأدنى الحدّ  كان الطبية، الوصفات في توصف التي الأدوية بعدد يتعلق وفيما
 تحتوي الوصفات الطبية  من ٪2.53 وحوالي 55.8 يساوي  المعياري والانحراف 54.0 الوصفة الواحدة كان  في الأدوية
 4كانت تحتوي على   ٪58 أنواع من الأدوية ، ونسبة 0كانت تحتوي على   ٪0.73 أنواع من الأدوية ، ونسبة 5 على
 التي الأدوية لمعظم وأكثر من ذلك .أما بالنسبة   انواع من الادوية 5كانت تحتوي على  %8.43, ونسبة أنواع من الأدوية
 ، ٪5.45 نسبة في الوصفات الطبية حيث بلغت نسبته  الأعلى الاسبيريندواء  كان السن، لكبار طبية وصفة في توصف
 من ٪2.0 الديجوكسين بأدنى نسبةبينما كان  ، ٪7.55 بنسبة  الباراسيتامولو ، ٪4.20الذي يمثّل نسبة  الاينالابريليليه 
 .الطبية الوصفات
 المدرجة الوصفات من %5.25الأدوية ، تظهر بين الضارة الدوائية التفاعلات إمكانية لدراسة الأدوية  فاحص  وبإستخدام
نسبة ب الخطيرةالضارة  الدوائية التفاعلات  تم ّ إظهار  وقد الضارة؛ الدوائية التفاعلات من مختلفة أنواع الدراسة في
 الطبية، الوصفات من ٪5.44 بنسبة  التي تظهرالهامة من الوصفات الطبية بالإضافة إلى التفاعلات الدوائية   %3.50
 %5.25 في عليها عثر الضارة الدوائية التفاعلات أن يعني وهذا .%34وتظهر نسبة التفاعلات الدوائية الضعيفة بنسبة 
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انواع ادوية  5في الوصفات اللتي تحتوي على  خطيراالتفاعل  وكان. الأونروا عيادات وصفت في  التي الوصفات من
 . الوصفات من ٪8.75بنسبة   هاما وكان الطبية، الوصفات من ٪3.45 بنسبة واكثر
 تفاعلاتبالليس لديهم معرفة  الأونروا عيادات في يعملون الذين الصحية الرعاية مقدّمي غالبية أن إلى الدراسة وخلصت
صحوبة م تدريب و متابعة برامج إلى حاجة وهناك. التحسين من إدارة الوصفات الطبية مزيداً  وتتطلب. الضارة الدوائية
 .والتعليم بالإشراف
 
 
 
